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ABSTRACT 
 
Cynthia A. Nagle 
Glycerol-3-Phosphate Acyltransferase Isoforms: Hepatic Triacylglycerol Synthesis and the 
Development of Insulin Resistance 
(Under the direction of Rosalind A. Coleman) 
 
Elucidation of the metabolic pathways of triacylglycerol synthesis is critical to the 
understanding of chronic metabolic disorders such as obesity, cardiovascular disease, and 
diabetes.  Glycerol-sn-3-phosphate acyltransferase (GPAT) and sn-1-acylglycerol-3-
phosphate acyltransferase (AGPAT) catalyze the first and second steps in de novo 
triacylglycerol synthesis.  These enzymes have multiple isoforms with different subcellular 
locations and tissue distributions.  The specific function of each isoform and its product in 
the regulation of TAG synthesis and intracellular signaling pathways is not completely 
understood.  This dissertation describes two separate projects.  The first project examines the 
role of GPAT1 and de novo glycerolipid synthesis in the development of hepatic steatosis 
and hepatic insulin resistance. The second project describes the identification of a novel 
GPAT isoform, GPAT4.  
 
In the first project, we used an adenoviral construct to overexpress glycerol-sn-3-
phosphate acyltransferase-1 (Ad-GPAT1) to determine whether increased glycerolipid flux 
can, by itself, cause hepatic insulin resistance.  We found that hepatic overexpression of 
GPAT1 caused hepatic TAG accumulation and hyperlipidemia without affecting body weight 
or adiposity.  This GPAT1-mediated increase in hepatic de novo glycerolipid synthesis 
 iii
 caused both systemic and hepatic insulin resistance, which was associated with elevated 
hepatic diacylglyerol and lysophosphatidic acid content, suggesting a role for these lipid 
metabolites in the development of hepatic insulin resistance. We identified a potential 
DAG/protein kinase C-mediated mechanism for hepatic insulin resistance, and we did not 
find any evidence for an immune mediated mechaninsm.   
 
 In the second project, we characterized the acyltransferase activity of AGPAT6.  
AGPAT6 was one of eight AGPAT isoforms identified through sequence homology, but the 
enzyme activity for AGPAT6 had not been confirmed.  The NEM-sensitive GPAT specific 
activity was 65% lower in liver and brown adipose tissue from Agpat6-/- mice than in tissues 
from wild type mice, but the AGPAT specific activity was similar in wild type and Agpat6-/- 
mice.  Cos-7 cells transfected with AGPAT6 had higher NEM-sensitive GPAT specific 
activity and no change in AGPAT activity.  Thus, we have identified a novel NEM sensitive 
GPAT isoform that is expressed in liver and brown adipose tissue.  We have named this 
isoform GPAT4.   
iv 
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CHAPTER I  INTRODUCTION 
 
 
 Excessive storage of triacylglycerol (TAG) in hepatocytes is associated with 
increased secretion of TAG in very low density lipoproteins (VLDL). Both fatty liver and 
increased VLDL have been implicated in the pathogenesis of insulin resistance and type 2 
diabetes, and they are also well known risk factors for atherosclerosis and cardiovascular 
disease. Prevention and treatment of these chronic diseases of lipid metabolism requires a 
better understanding of the regulation of hepatic TAG synthesis.  
 
 Glycerol-3-phosphate acyltransferases (GPAT) catalyze the first committed step in de 
novo synthesis of TAG and other glycerolipids.  There are 3 cloned GPAT isoforms - one 
located in the endoplasmic reticulum,GPAT3, and 2 located in mitochondria, GPAT1 and 
GPAT2 [1].  Approximately 50% of total liver GPAT activity is an N-ethylmaleimide (NEM) 
resistant activity located in mitochondria, and the other 50% is an ER-located NEM-sensitive 
activity.  GPAT1, which is resistant to NEM, is highly expressed in liver and adipose tissue.  
Studies with GPAT1-/- mice indicate that GPAT1 is the primary mitochondrial GPAT 
isoform in liver [2].  GPAT2 is highly expressed in testes, and its activity in liver is low 
under normal conditions [3].  GPAT3, the only identified erGPAT, is NEM-sensitive, and its 
mRNA expression is high in white adipose tissue, but not liver [4, 5].  Thus, GPAT3 may not 
be the primary erGPAT in liver.  GPAT3 was originally classified by Vergnes et al. as 1-sn
 
 acylglycerol-3-phsophate acyltransferase-8 (AGPAT8) based on amino acid sequence 
homology to AGPAT1 and AGPAT2, which share similar conserved acyltransferase motifs 
with GPAT isoforms [4].  Another AGPAT isoform, AGPAT6, is 66% homologous to 
AGPAT8, and AGPAT6 is relatively highly expressed in liver tissue.  Mice deficient in 
AGPAT6 have reduced TAG mass in adipose tissue and liver, indicating that AGPAT6 is 
important for hepatic TAG synthesis.  The phenotype of AGPAT6-/- mice is consistent 
with a deficiency in either AGPAT or GPAT activity, but the specific acyltransferase 
activity of AGPAT6 had not been confirmed. 
 
 Work in our laboratory with GPAT1-/- mice and with primary hepatocytes that over-
express GPAT1 suggests an important role for GPAT1 in the synthesis of TAG destined for 
intracellular storage.  GPAT1-/- mice have low liver and VLDL TAG mass, and decreased 
VLDL secretion [2].  However, adenoviral over-expression of GPAT1 in rat primary 
hepatocytes increases TAG accumulation without increasing TAG secretion into culture 
media. Because systemic GPAT1 deficiency decreased plasma TAG levels but GPAT1 
overexpression failed to increase secretion of labeled TAG from hepatocytes, the role of 
GPAT1 in the synthesis of TAG for incorporation into VLDL is not clear.   
 
Despite the association of hepatic steatosis with insulin resistance, and the 
amelioration of hepatic triacylglycerol accumulation with improved insulin sensitivity, it is 
still unclear whether insulin resistance causes the increase in hepatic triacylglycerol or 
whether the increase in glycerolipid intermediates or triacylglycerol itself plays a causal role 
in hepatic or systemic insulin resistance [6-12].  Most animal models of hepatic steatosis and 
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 insulin resistance have been created through high-fat or high-sucrose feeding or through 
genetic disruption of insulin or leptin signaling pathways.  Diet-induced hepatic steatosis, 
however, is not a good model for isolating the role of the liver in the pathogenesis of insulin 
resistance because high-fat diets cause weight gain and obesity, which independently 
contribute to the development of systemic insulin resistance.  Systemic deficiencies in leptin 
or insulin signaling also cause obesity by increasing centrally-mediated food intake.  An 
animal model that isolates the accumulation of triacylglycerol in liver from its 
accumulation in other tissues may provide a better understanding of the role of hepatic 
lipid synthesis or accumulation in the development of hepatic and peripheral insulin 
resistance.   
 
 Hepatic overexpression of GPAT1 may be an ideal model to examine the role of 
hepatic de novo glycerolipid synthesis in the development of insulin resistance. GPAT1-/- 
mice have reduced hepatic lysophosphatidic acid (LPA), DAG and TAG content [13].  When 
fed a high-fat safflower oil diet for 3 weeks, GPAT1-/- mice are protected from high-fat diet-
induced insulin resistance, suggesting that a glycerolipid metabolite may be involved in the 
mechanism of high-fat-diet-induced hepatic insulin resistance [14].  GPAT1 mRNA 
expression is increased in livers from ob/ob and high-fat-fed mice, suggesting that enhanced 
GPAT1 activity could play a role in the pathogenesis of insulin resistance [15].  However, 
the specific role of hepatic de novo glycerolipid synthesis in the development of systemic 
insulin resistance is not completely understood.   
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 1.1  SPECIFIC AIMS: 
 
 
Aim 1.  To determine whether liver-specific overexpression of GPAT1 causes fatty 
liver and hyperlipidemia 
 
Aim 2:  To determine whether GPAT1 over-expression in liver leads to the 
development of hepatic or whole-body insulin resistance. 
 
Aim 3:  To determine the mechanism(s) of hepatic insulin resistance in Ad-GPAT-
treated rats. 
 
Aim 4.  To identify and characterize the mouse liver erGPAT isoform(s).  
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CHAPTER II.   LITERATURE REVIEW 
 
 
2.1 Triacylglycerol Metabolism in Health and Disease 
The regulation of triacylglycerol (TAG) synthesis and metabolism plays an important 
role in whole body energy homeostasis in mammals.  TAG is synthesized in hepatocytes 
when glucose is abundant.  Newly synthesized TAG is either stored within hepatocytes in 
intracellular droplets as an energy reserve, or packaged in VLDL particles that are released 
into the blood and carried to skeletal muscle, heart, and adipose tissue for oxidation or 
storage. In mammals, the primary site of TAG storage is in adipose tissue, which is designed 
to accumulate large quantities of stored TAG.  When glucose supply to the body is limited, 
stored TAG is released from adipose stores as free fatty acids (FFA) and glycerol, which are 
oxidized by other tissues.  However, when TAG oxidation and synthesis are not properly 
regulated, TAG can accumulate in non-adipose tissues as well as in adipose tissue, and the 
excessive accumulation of intracellular TAG has been implicated in the pathogenesis of 
obesity, cardiovascular disease, insulin resistance, and type 2 diabetes [16].  Cardiovascular 
disease (CVD) is the number one cause of death in U.S. adults, and the prevalence of obesity 
and type 2 diabetes, both risk factors for CVD, are increasing at alarming rates [17].   
Expanding our basic understanding of TAG metabolism, its regulation, and its role in the 
pathogenesis of chronic diseases is important for developing effective treatments and prevention 
strategies for obesity-related disorders. 
 
 2.2 De novo Triacylglycerol Synthesis 
Triacylglycerol  (TAG) synthesis begins with activation of long chain fatty acids to 
acyl-Coenzyme A (CoA) thioesters by the enzyme acyl-Coenzyme A synthetase.  Then, sn-
glycerol-3-phosphate acyltransferase (GPAT) esterifies fatty acids to glycerol-3-phosphate at 
the sn-1 position, forming lysophosphatidic acid (LPA).  This first esterification step 
commits fatty acids to TAG or phospholipid synthesis (Figure 2.1).  LPA is acylated by 1-
acyl-sn-glycerol 3-phosphate acyltransferase (AGPAT) at the sn-2 position to form 
phosphatidic acid (PA).  Phosphatidate phosphohydrolase (also known as lipin) hydrolyzes 
the phosphate group at the sn-3 position of PA to form diacylglycerol (DAG).  
Diacylglycerol acyltransferase (DGAT) acylates DAG at the sn-3 position to complete the 
final step in TAG synthesis [18].  All of the enzymes of de novo TAG synthesis have 
multiple isoforms, but the exact role of each isoform in the regulation of de novo glycerolipid 
synthesis and in the intracellular channeling of glycerolipid intermediates to specific 
downstream pathways has not been elucidated [19].   
 
2.3 Glycerol-sn-3-Phosphate Acyltransferase Isoforms 
Glycerol-sn-3-phosphate acyltransferase acylates glycerol-3-phosphate (G3P) at the 
sn-1 position of the glycerol backbone to form 1-acyl-sn-glycerol-3-phosphate, or 
lysophosphatidic acid (LPA) [20, 21] (Figure 2.1).  This step commits acyl-CoAs to de novo 
glycerolipid synthesis, and it may be the rate-limiting step, as GPAT has the lowest specific 
activity of all of the enzymes in that pathway [22, 23]. When this dissertation project was 
initiated there were two known mammalian GPAT activities – a mitochondrial activity that 
was resistant to inhibition by the sulfhydryl reagent N-ethylmaleimide (NEM) (called 
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 mtGPAT), and a microsomal activity that was sensitive to inhibition by NEM (called 
erGPAT) [24].  The enzyme responsible for the NEM-resistant mitochondrial activity had 
been purified and cloned (GPAT1) [25-27], but no NEM-sensitive erGPAT had been cloned. 
In the last several years, multiple mitochondrial and microsomal GPAT isoforms have been 
identified and cloned.  There are now 4 known GPAT isoforms, 2 mitochondrial GPATs 
[GPAT1 (formerly mtGPAT) and GPAT2], and two microsomal GPATs (GPAT3 and 
GPAT4).  GPAT isoforms 1-3 are described in this chapter, and the identification of GPAT4 
will be described in Chapter 3. 
 
2.3.1 GPAT1 
2.3.1.1 GPAT1 Enzyme Structure: 
GPAT1 has been cloned from both mouse (827 a.a.) and rat (828 a.a) liver, and has 
also been purified from rat liver [25-27]. Located in the outer mitochondrial membrane, 
GPAT1 has 2 transmembrane domains ( 472-493 a.a. and 576-592 a.a.), with the N and C 
terminal ends facing the cytosol and a loop structure (494-575 a.a.) facing the intermembrane 
space of the mitochondrion [28].  The active-site is located on the N terminal domain and 
faces the cytosol, indicating that LPA is released into the cytosol or into the cytosolic face of 
the mitochondrial bilayer. LPA synthesiszed by GPAT1 is either acylated by a mitochondrial 
AGPAT isoform (none have been cloned), or it must travel from the mitochondria to the 
endoplasmic reticulum, where the downstream enzymes of glycerolipid synthesis are located 
[22].  Although the exact mechanism for the transport of LPA from mitochondria to the ER 
are not known, liver-fatty acid binding protein (L-FABP) has been shown to transport LPA 
from mitochondria to the ER for PA synthesis in vitro [29]. 
7 
GPAT1 shares conserved active site and substrate binding motifs with other 
acyltransferases, including AGPAT isoforms (Table 2.1)[29].  Site-directed mutagenesis of 
conserved amino acids in Motifs I-IV of E. coli GPAT indicate that Motifs I, III, and IV are 
involved in catalysis, whereas Motifs II and III are important for glycerol-3-phosphate 
binding [30].  Although the essential catalytic motifs are on the N-terminus, site-directed 
mutagenesis of the loop structure that faces the intermembrane space decreases enzyme 
activity, suggesting a critical structural or regulatory role of this domain [28].  Truncation of 
the C-terminus also inactivates GPAT1, suggesting that the N- and C-termini are both 
required for GPAT activity [31].  Crosslinking studies of GPAT1 truncation mutations 
indicate that the N- and C-terminal regions interact [31].  This interaction of termini may be 
involved in the post-translational regulation of GPAT1 by adenosine monophosphate 
activated protein kinase (AMPK), as phosphorylation of two AMPK consensus binding 
domains on the C-terminal end could alter the interaction between the termini, and thus 
decrease enzyme activity [31].    
 
2.3.1.2 GPAT1 Tissue Expression and Activity: 
Because GPAT1 activity is resistant to NEM, its activity can be distinguished from all 
other known GPAT isoforms in total cellular membrane fractions in liver.  Purified GPAT1 
has a substrate preference for 16:0-CoA compared to 18:0-CoA or 18:1-CoA, but it can use a 
variety of long-chain acyl-CoAs [25].  GPAT1 mRNA is expressed in most tissues, but it is 
most highly expressed in liver, adipose tissue, muscle, kidney, and brain [29, 32].  Protein, 
mRNA, and activity levels do not correlate well to each other, and the correlation varies in
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Table2.I: Acyltransferase motifs in E. coli and mouse GPAT and AGPAT isoforms  
 Motif Ia Motif IIa Motif IIIa Motif IVa Motif Vf
Functiona Catalysis  G-3-P binding G-3-P binding Catalysis  
E. coli GPAT 
(plsB) (BAE78043) 306 HRSHMD 349 GAFFIRR 383 FVEGGRSR 417 ITLIPIYIGYE 
 
GPAT1b  
(NP_032175) 
230 HRSHID 272 GGFFIRR 313 FLEGTRSR 347 ILVIPVGISYD  
GPAT2c 
(NP_001074558) 
202 HKSLLD   
231 TCSPALR   
    or 
235 ALRALLR  
    or 
247 LGGFLPP[33] 
291 GSPGRLSA  
    or 
285 FLEEPPGS[33]  
320 ATLVPVAIAYD 
 
GPAT3 (AGPAT8d) 
(NP_766303) 
229 HRTRVD 268 VHIFIHR 301 FPEGTCLT 324 GTIYPVAIKYN 366 VWYMPPMTREEGED 
GPAT4 (AGPAT6e) 
(NP_061213) 
248 HTSPID 286 PHVWFER 320 FPEGTCIN 343 ATVYPVAIKYD 385 VWYLPPMTREKDED 
AGPAT1 
(NP_061350) 
104 HQSSLD 140 GIIFIDR 173 FPEGTRNH 200 VPIIPIVNSSY 231 VLPPVSTEGLTPDD 
AGPAT2 
(NP_080488) 
98  HQSLID 137 GVYFINR 170 YPEGTRND 197 VPIIPVVYSSF 227 VLDAVPTNGLTDAD 
AGPAT3 
(NP_443747) 
96  HNFEID   138 EIVFCKR 174 YCEGTRFT 202 YHLLPRTKGF  
AGPAT4 
(NP_080920) 
96  HKFEID   138 EMIFCTR 174 HCEGTRFT 202 HHLLPRTKGF  
AGPAT5 
(NP_081068) 
93  HQSTVD  137 GGIYVKR 171 FPEGTRYN 202 HVLTPRIKAT  
AGPAT7 
(NP_997089) 
129 HSTFFD 166 QAILVSR 201 FPEGTCSN 224 VPVQPVLIRY  
9
 
aAcyltransferase motifs as we described in [30].  Bolded residues are highly conserved across these GPAT family members.  
Underlined amino acids are important for GPAT1 activity as determined by mutagenesis [29, 30]. Cysteines that may be targets for N-
ethylmaleimide are highlighted and italicized.  bPreviously called mtGPAT or mtGAT. cAlso identified as xGPAT1 [33].  dIdentified 
in GenBank as AGPAT8, but has only GPAT activity [34].  eIdentified in GenBank as AGPAT6, but has only GPAT activity as 
reported here. fMotif V as described in [35]. 
 
 
 different tissues [32].  Rat liver and adipose tissue have the highest GPAT1 specific activities 
[32]. The discrepancies between GPAT1 mRNA and protein expressions and activities 
indicate that GPAT1 may be regulated post-transcriptionally and post-translationally [32].  In 
most tissues, GPAT1 activity accounts for 10-20% of the total GPAT activity, whereas NEM 
sensitive GPAT activity accounts for 80-90% of the total GPAT activity [29].  In liver, 
however, GPAT1 activity accounts for 40-50% of the total GPAT activity, suggesting a 
specific role for GPAT1 in liver glycerolipid synthesis [29].  
 
2.3.1.3  GPAT1 As a Key Regulator of TAG Synthesis 
Despite its location on the mitochondrial outer membrane and the fact that the 
terminal enzymes required for TAG synthesis are located in the ER (Figure 1), GPAT1 plays 
an important role in the synthesis of TAG [2, 36-38].  When GPAT1 is overexpressed in 
Chinese hamster ovary (CHO) cells in the presence of trace [14C]oleate, label incorporation 
into DAG and TAG increase 2-fold, and TAG mass also increases 2-3-fold, whereas label 
incorporation into phospholipids decreased by 30% [38].  However, in primary hepatocytes 
treated with trace [14C]oleate, a slight increase in PC synthesis (28%) and a >2-fold increase 
in DAG synthesis is observed in the absence of a significant change in TAG synthesis [36].  
When primary hepatocytes are incubated with 100-750 µM oleate, [14C]oleate incorporation 
into DAG and TAG increase >2-fold, while acid soluble metabolites and CO2 production are 
reduced 50-80% [36, 37].  Slight increases in PL synthesis are also observed when GPAT1-
treated primary hepatocytes were incubated with exogenous fatty acid, but the increases in 
DAG and TAG were more pronounced [36, 37]. Although an increase in hepatic TAG might 
cause increased TAG secretion into the cell culture media from hepatocytes, no significant 
10 
 increase in media TAG was observed in two independent studies of GPAT1 overexpression 
in primary hepatocytes [36, 37].  These studies in cell culture systems suggested that GPAT1 
primarily directs exogenous fatty acids toward TAG synthesis, rather than toward PL 
synthesis pathways or β-oxidation, but the role of GPAT1 in the regulation of TAG secretion 
from liver cells is not clear from these in vitro models.   
 
Several animal models have been developed to examine the role of GPAT1 in TAG 
synthesis in vivo. Compared to wild-type mice, mice that are deficient in GPAT1 (GPAT1-/-) 
have 37% lower liver TAG content, lower TAG secretion, lower body weight, lower gonadal 
fat pad weight, and lower plasma cholesterol levels[2].  Incorporation of palmitate (16:0) into 
TAG and PL was significantly lower in liver from GPAT1-/- mice, supporting the preference 
of GPAT1 for palmitate.  When fed a high sucrose/high saturated fat (HH) diet for 4 months 
or a high-fat safflower oil diet for 3 weeks, GPAT1-/- mice had a 60% lower hepatic TAG 
content than wild-type controls, and a 2-fold increase in plasma β-hydroxybutyrate 
concentration, indicating that lack of GPAT1 in liver altered fatty acid metabolism to favor 
oxidation over TAG synthesis [13, 14].  Liver-specific knock-down of GPAT1 with antisense 
oligonucleotides in obese and diabetic ob/ob mice also reduced hepatic TAG and DAG 
content with little effect on hepatic phospholipid or cholesterol content, further supporting a 
role for GPAT1 in the regulation of TAG synthesis [39]. While these studies all suggest that 
GPAT1 is important in regulating hepatic TAG synthesis, the effects of GPAT1 on plasma 
TAG concentrations were not clear, as GPAT1-/- mice had lower plasma TAG concentrations 
compared to wild-type controls in  
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Figure 2.1: GPAT isoforms located in mitochondria (GPAT1 and GPAT2) and ER (GPAT3 and GPAT4) 
catalyze the initial step in the de novo synthesis of phospholipids and triacylglycerol (TAG).  Acyl-CoA use for 
β-oxidation or TAG synthesis is regulated reciprocally by carnitine palmitoyl transferase 1 (CPT-1) and GPAT1 
(mtGPAT).  Lysophosphatidic acid (LPA), phosphatidic acid (PA), diacylglycerol (DAG), very low density 
lipoprotein (VLDL).  
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some studies [2, 14], and not in others [13, 39].  The effects of GPAT1 on plasma cholesterol 
content were more consistent, with reduced hepatic GPAT1 activity correlating with lower 
plasma cholesterol in 3 out of 4 studies [2, 13, 14, 39]. 
 
Hepatic overexpression of GPAT1 in mice [15] and rats (see Chapter 3)[40] also 
supports a role for GPAT1 in TAG synthesis. Mice treated with an adenovirus that expresses 
GPAT1 had a 3.5-fold increase in hepatic TAG, and fatty acid oxidation was reduced in liver 
slices from Ad-GPAT1-treated mice [15]. Taken together, studies of GPAT1 overexpression 
and knock-down studies in rodents support the hypothesis that GPAT1 and CPT1 compete 
for acyl-CoAs at the mitochondrial membrane, and that GPAT1 primarily channels these 
acyl-CoAs towards TAG synthesis.  The role of GPAT1 in the secretion of TAG from liver is 
still not completely understood, but over expression of GPAT1 in rodents increases TAG and 
plasma cholesterol concentrations (see Chapter 3)[15, 40]. 
 
2.3.1.4 GPAT1 Transcriptional Regulation  
Transcription of the GPAT1 gene is primarily regulated by insulin, which is 
consistent with the hypothesis that GPAT1 plays a prominent role in regulating TAG 
metabolism.  Hepatic GPAT1 mRNA levels decrease dramatically in rats that were fasted for 
48 h, and both gene expression and enzyme activity levels increase when the rats are re-fed a 
high sucrose, low-fat diet [32].  The response of GPAT1 gene expression to fasting and re-
feeding is regulated by insulin, as hepatic GPAT1 gene expression does not respond to 
fasting and re-feeding in streptozotocin-induced diabetic rodents, which do not produce 
insulin [41].  When insulin is administered to these rodents, liver GPAT1 mRNA levels 
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 increase, as do sterol regulatory element binding protein-1c (SREBP1-c) mRNA levels.[41, 
42].  SREBP1-c is a transcription factor that regulates the expression of multiple lipogenic 
enzymes, including FAS, ACC, and SCD-1 [43-46].  Insulin up regulates the transcription of 
SREBP1-c, and active SREBP-1c binds to SREs or E-box motifs in the promoters of its 
target genes [29].  The murine GPAT1 promoter contains response elements for the 
transcription factors sterol SREBP-1c and for NF-Y (nuclear factor Y), and GPAT1 
expression increases in 3T3-L1 adipocytes with ectopic expression of SREBP-1c or SREBP-
1a [47]. GPAT1 gene expression is also up regulated in liver and adipose tissue by both 
SREBP-1a and -1c [48].    
 
Carbohydrate may increase GPAT1 gene expression by enhancing the binding of 
carbohydrate response element binding protein (ChREBP) to carbohydrate response elements 
(ChRE) in the GPAT1 promoter [49]. ChREBP is a transcription factor that is activated by 
xyulose 5-P, and it regulates many of the genes involved in hepatic lipogenesis [50, 51].  In 
ChREBP-/- mice, an SREBP-1c agonist still fully activates the GPAT1 transcript, suggesting 
that ChREBP is not required for the SREBP-1c-mediated activation of GPAT1 expression 
[52]. However, it is still unknown whether ChREBP can activate GPAT1 transcription 
independently of SREBP-1c.  The liver X receptor (LXR) is the key lipogenic regulatory 
transcription factor in liver because it regulates the expression of both SREBP-1c and 
ChREBP [52].  Thus, activation of LXR through insulin signaling or oxysterol binding to 
LXR can activate GPAT1 expression indirectly through its activation of SREBP-1c 
expression [52].  
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 2.3.1.5 Acute Regulation of GPAT1   
Although no one has shown direct phosphorylation or dephosphorylation of GPAT1, 
there is mounting evidence that GPAT1 activity is acutely regulated by phosphorylation and 
dephosphorylation events.  GPAT1 activity is negatively regulated by the cellular energy 
sensor, AMP-activated protein kinase (AMPK).  AMPK becomes active when cellular ATP 
levels fall and cellular AMP levels rise, and it inactivates anabolic pathways in favor of 
catabolic pathways [53].  AMPK phosphorylates and inactivates ACC, thus decreasing 
cellular concentrations of malonyl-CoA, a potent inhibitor of CPT-1, and increases acyl-CoA 
entry into mitochondria for β-oxidation [53].  Incubation of rat liver total membranes with 
purified recombinant AMPK inhibits GPAT1 activity, and treating primary rat hepatocytes 
with 5-amino-4-imidazolecarboxamideriboside (AICAR), an activator of AMPK, inhibits 
radio labeled glycerol incorporation into glycerolipids [54].  Exercise, which increases 
cellular energy needs, activates AMPK, and decreases GPAT1 activity in liver and adipose 
tissue, but not in skeletal muscle [55].  Thus, AMPK reciprocally regulates the partitioning of 
acyl-CoAs into oxidative and glycerolipid synthetic pathways by inhibiting GPAT1 while it 
activates CPT-1 by inhibiting ACC and producing malonyl-CoA. 
 
In addition to acute regulation by AMPK, GPAT1 activity is also regulated by casein 
kinase II (CK2). Casein kinase II is a constitutively active cytosolic serine/threonine kinase 
that is involved in multiple cellular processes, including regulation of the cell cycle and DNA 
repair [56]. Only a few metabolic enzymes are known to be regulated by CK2, including 
ACC and glycogen synthase [56]. Treating rat mitochondria with CK2 increases GPAT1 
activity 2-fold, and there are several putative CK2 binding sites in the GPAT1 protein 
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 sequence [57].  Because CK2 is constitutively active, its physiological role in GPAT1 
regulation is not clear. 
 
2.3.2  GPAT2:    
2.3.2.1 Structure of GPAT2 
GPAT2 is a 798-801 a.a. protein that is 27%-32% identical to GPAT1 [58, 59]. The 
active site region of GPAT2 contains acyltransferase motifs I and IV, but motifs II and III 
differ from those of GPAT1 and are more closely related to those of squash chloroplast 
GPAT [59].  At least two transmembrane domains are predicted for the GPAT2 protein 
structure, one at 446-474 a.a., and another at 156-177 a.a. [59].  Two other potential 
transmembrane domains (204-226 or 301-329 a.a.) seem unlikely because they include the 
active site motifs and would place portions of the active site on opposite sides of the 
membrane [59].  Assuming that the two transmembrane domains do not include the active 
site motifs, the predicted topology for GPAT2 would place both N and C termini in the 
intermembrane space, with the active site in the loop region facing the cytosol [59].  The 
open reading frame for GPAT2 encodes an 88 kDa protein, but GPAT2 undergoes 
posttranslational modification in some tissues (brown adipose tissue) and cell culture lines 
(Cos-7 cells and HEK cells) that results in an 80 kDa protein [59].  The significance of this 
post-translational modification on GPAT2 activity, subcellular location, or function, is not 
known. 
 
 
 
16 
 2.3.2.2  GPAT2 Activity and Tissue Expression 
Although structurally similar, GPAT1 and GPAT2 have different sensitivities to 
sulfhydryl reagents, have different substrate preferences, and have different patterns of 
expression in mouse tissues. Unlike GPAT1, GPAT2 is an NEM sensitive mitochondrial 
GPAT [3].  GPAT2 is expressed in mouse testis, heart, liver, spleen, kidney, white and 
brown adipose tissue, and in 3T3-L1 pre- and post adipocytes [58, 59]. GPAT2 does not 
prefer palmitoyl-CoA as its substrate, and it does not have a substrate preference [3].   Unlike 
GPAT1, GPAT2 has low expression and activity in normal mouse liver, but it was up 
regulated in GPAT1-/- mouse liver, where its activity was originally characterized [3, 59]. 
This up regulation indicates that GPAT2 may have functional redundancies with GPAT1, but 
the redundancies are not significant enough to suppress the phenotype of GPAT1-/- mice.  
Thus, GPAT2 may also have unique functions that are not shared by GPAT1.  When GPAT2 
is overexpressed in Cos-7 cells, there is an 85% increase in [14C]-oleate incorporation into 
TAG, while label incorporation into phospholipids is reduced 13 % [59]. These results 
suggest that GPAT2 is involved in TAG synthesis, but because GPAT2 activity and 
expression are not readily detectible in wild-type mouse liver, GPAT2 may not play an 
important role in liver TAG synthesis under normal physiologic conditions.  Unlike GPAT1, 
rat liver GPAT2 expression and activity are not regulated by fasting and re-feeding, 
indicating that GPAT2 does not play a major role in TAG synthesis in response to nutritional 
status [59]. GPAT2 may play a unique role in testis lipid metabolism, and the promoter of 
GPAT2 contains hormone response elements for glucocorticoids, estrogen, and progesterone 
that could regulate its expression in testis [59]. Further studies are needed to identify the 
specific role of GPAT2 in the regulation of TAG and PL synthesis in liver and other tissues.   
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2.3.3  GPAT3  
Recently, the gene product previously called AGPAT8 in the NCBI database was 
shown to have NEM-sensitive GPAT activity and to lack AGPAT activity; this gene product 
was re-named GPAT3 [34].  GPAT3 is a 438 a.a. protein that contains all four conserved 
acyltransferase motifs, and like GPAT1 and 2, it is predicted to have at least 2 
transmembrane domains [5].  GPAT3 is located in the endoplasmic reticulum, making it the 
first erGPAT to be identified [5]. Like GPAT2, GPAT3 recognizes a broad range of acyl-
CoA species, and it has the highest activity with l6-18 carbon acyl-CoA species [5]. GPAT3 
was highly expressed in mouse white adipose tissue (WAT), small intestine, brown adipose 
tissue (BAT), kidney, heart and colon[5].  The expression and activity of GPAT3 increase 
during the differentiation of 3T3-L1 preadipocytes, and siRNA knockdown of Gpat3 in 3T3-
L1 adipocytes reduces total GPAT activity by ~60% [4, 34], it is likely that GPAT3 is 
important for TAG synthesis in WAT. Expression of GPAT3 in WAT may be regulated by 
the transcription factor peroxisome proliferator gamma (PPARγ), because GPAT3 mRNA 
increased 5-fold in WAT from ob/ob mice treated with rosiglitizone [5]. Although GPAT3 
appears to be the major erGPAT isoform in WAT, GPAT3 is unlikely to play a major role in 
TAG synthesis in liver where its mRNA expression is very low [4, 5].  Since 50% of the 
GPAT activity in liver is a microsomal NEM-sensitive activity, it is possible that another 
erGPAT isoform exists (see Chapter 3). 
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 2.4  1-Acyl-sn-Glycerol-3-Phosphate Acyltransferase Isoforms 
1-Acyl-sn-glycerol-3-phosphate acyltransferase (AGPAT) acylates LPA at the sn-2 
position to form PA. There were 8 named AGPAT isoforms (AGPAT1-8), all of which share 
sequence homology with GPAT isoforms at the conserved motifs I-IV (Table 2.1) [29].  
AGPAT1 and AGPAT2 have been shown to have robust AGPAT activity [60, 61], but the 
activities of AGPAT3-7, which were identified by sequence homology to AGPAT1 and 2, 
have either not been characterized, or were reported to have very low AGPAT activity 
compared to AGPAT1 and 2 [62, 63].  AGPAT8 has recently been re-characterized as an 
NEM-sensitive GPAT and has been re-named GPAT3 [5].   
 
2.4.1  AGPAT1 
Human AGPAT1 is a 283 a.a. protein that is located in the endoplasmic reticulum 
when overexpressed in CHO cells [60].  AGPAT1 prefers 16:0, 18:0, or 18:1-CoA over 20:0 
or 20:4-CoA, suggesting that AGPAT1 is not responsible for the enrichment of glycerolipids 
with 20:4 at the sn-2 position [29, 60].  AGPAT1 is expressed in most tissues, with high 
levels of expression in mouse BAT, brain, and visceral WAT, and human liver, heart, 
immune cells, and epithelium [4, 61, 64, 65]. Although few functional studies of AGPAT1 
have been done, overexpression of AGPAT1 in adipocytes suggests that AGPAT1 is 
involved in TAG synthesis [66].  AGPAT1 may play an important role in mediating PA 
signaling for immune responses, as the AGPAT1 gene has been mapped to the class III 
region of the human major histocompatibility complex [60]. Additionally, overexpression of 
AGPAT1 can enhance IL-1β-mediated TNFα and IL-6 release from ECV304 cells [65].   
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2.4.2  AGPAT2   
Human AGPAT2 is a 278 a.a. protein that shares 35% amino acid identity with 
AGPAT1 [65].  Unlike AGPAT1, AGPAT2 has a preference for 20:4-CoA, suggesting that it 
is the AGPAT isoform responsible for the common placement of arachidonic acid at the sn-2 
position of phospholipids [61].  AGPAT2 mRNA is expressed in most human tissues, but its 
expression is highest in heart and liver in humans and in adipose tissue in mice [4, 61].  
Patients with congenital generalized lipodystrophy are deficient in adipose tissue stores of 
TAG, and this deficiency in adipose tissue TAG has been associated with loss-of function 
mutations in AGPAT2 [67, 68].  Pre-adipocytes deficient in AGPAT2 do not differentiate 
into mature adipocytes, and C/EBPβ and PPARγ induction during early adipocyte 
differentiation is suppressed [69].  Knock-down of AGPAT2 in mature adipocytes reduces 
TAG mass by 50%, suggesting a key role for AGPAT2 in TAG synthesis [69].  Thus, 
AGPAT2 may play an important role in generating PA both for TAG synthesis and for 
intracellular signaling events important for preadipocyte differentiation [69].  In addition to 
its role in adipose tissue differentiation and metabolism, AGPAT2 may play an important 
role in carcinogenesis, as AGPAT2 expression in up regulated in several tumor cell lines 
[70].  PA generated by AGPAT2 supports Raf activation in the Ras/Raf/ERK pathway that 
enhances cell proliferation, and pharmacological inhibition of AGPAT2 inhibits cellular 
growth and initiates apoptosis in tumor cells [71].  Thus, AGPAT2-derived PA seems to be 
important for both TAG synthesis and for intracellular signaling pathways related to cellular 
differentiation and survival.   
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2.4.3  AGPAT3-5, and 7 
No functional studies of AGPAT3-5 or 7 have been reported, so their role in TAG 
synthesis is not known.  AGPAT activities for AGPAT3-5 have been reported, but the 
activities were barely above background AGPAT activity in Cos-7 cells, and they were also 
low in comparison to those measured for AGPAT2 in the same cells [63]. Thus, it is possible 
that AGPAT3-5 catalyze other acyltransferase activities besides AGPAT activity. AGPAT3-
5 expression increases during 3T3-L1 adipocyte differentiation, but the level of expression is 
much lower than that of AGPAT2, indicating that these isoforms may not be as important for 
adipocyte TAG synthesis as AGPAT2 [69].  In mice, AGPAT3 and 5 are expressed in liver, 
WAT, and BAT [4].  Unlike other AGPATs, AGPAT4 and AGPAT7 have very high mRNA 
expression in mouse brain [4].  Further studies are needed to characterize the roles of these 
AGPAT isoforms in TAG and PL synthesis and in intracellular signaling pathways, and to 
determine whether they have GPAT activity.  
 
2.4.4  AGPAT6 Knock-out Mice 
AGPAT6 plays an important role in TAG synthesis in subdermal adipose tissue, 
WAT,  and BAT, as mice deficient in AGPAT6 have a 90 % reduction in subdermal TAG, 
and a 40% and 30% reduction in TAG in WAT and BAT, respectively [4]. Liver TAG 
content and plasma TAG concentration are reduced 50% in AGPAT6-/- mice, suggesting that 
AGPAT6 is important for liver TAG synthesis and for the secretion of TAG from the liver.  
AGPAT6 deficiency protected ob/ob and high-fat/high-carbohydrate fed mice from obesity 
[4].  AGPAT6 is also important for TAG synthesis in mammary epithelial cells, as AGPAT6-
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 /- dams produce milk deficient in DAG and TAG, and the pups must be fostered to survive 
[35].  Together, these studies indicate an important role for AGPAT6 in TAG synthesis in 
adipose tissue, mammary tissue, and liver.  No studies have been done to examine the 
transcriptional regulation of AGPAT6, and the specific acyltransferase activity of AGPAT6 
was not confirmed when it was overexpressed in insect cells [35].  The phenotype of the 
AGPAT6-/- mice is consistent with a deficiency in a glycerolipid acyltransferase.  Thus, 
AGPAT6 could have GPAT activity (see Chapter 4). 
 
2.5  Are There More Than 3 GPAT Isoforms? 
Evidence that more than 3 isoforms of GPAT exist is growing. For several decades, 
only two GPAT activities were recognized, a mitochondrial NEM-resistant activity, and a 
microsomal NEM-sensitive activity.  The NEM-sensitive activity is generally 90% of the 
activity in most tissues, while the NEM-resistant activity accounts for 10% of the activity 
[24].  In liver, however, the NEM-resistant and NEM-sensitive activities each account for 
~50% of the total GPAT activity[24].  The recent identification of GPAT2 and GPAT3 
complicates the picture of GPAT activity in hepatocytes and other cells.  Each known GPAT 
isoform has a different profile of tissue expression, suggesting that each isoform plays a 
specific role in different tissues.  For instance, GPAT2 may have an important role in testis 
glycerolipid metabolism, but it probably has a minor role in hepatic TAG synthesis [59].  
GPAT3 is the first erGPAT identified, and its tissue expression pattern and role in 3T3-
adipocyte differentiation indicate that it is important for regulating TAG synthesis in WAT 
[4, 5, 72].  Approximately fifty percent of total hepatic GPAT activity is NEM-sensitive and 
microsomal, but GPAT3 may not be responsible for all this activity because GPAT3 gene 
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 expression in liver is very low compared to its expression in WAT [4].  Thus, another NEM-
sensitive erGPAT isoform may exist.  GPAT3 was originally classified as an AGPAT 
(AGPAT8) based on amino acid sequence homology to AGPAT1 and AGPAT2, and the 
specific acyltransferase activity of several other named AGPAT isoforms has not been 
confirmed (Vergnes, 2006).  AGPAT6 shares 66% amino acid sequence homology with 
GPAT3 (AGPAT8), and its expression in liver is relatively high [4, 5].  AGPAT3 and 
AGPAT5 are also expressed at relatively high levels in liver.  The specific acyltransferase 
activity of these “AGPAT” isoforms needs to be characterized to confirm that they have 
AGPAT activity.  It is possible that one or more of the “AGPAT” isoforms actually has 
GPAT activity. 
 
2.6  Why Are There So Many GPAT and AGPAT Isoforms? 
The identification of multiple GPAT and AGPAT isoforms with different subcellular 
locations and tissue expression patterns is somewhat puzzling.  Why does a cell need so 
many enzymes to make precursors for phospholipid and TAG?  One possibility is that 
different GPAT and AGPAT isoforms are assigned to channel acyl-CoAs to PL synthesis vs. 
TAG synthesis.  In this case, GPATs designated to channel LPA to PL synthesis might be in 
close proximity on the mitochondrial or endoplasmic reticulum membranes to AGPATs 
designated to make PA for PL synthesis.  The fact that functional studies of all 3 of the 
known GPAT isoforms suggest that all 3 are involved in TAG synthesis makes this first idea 
seem unlikely [19].  Another possibility is that the reason for multiple GPAT and AGPAT 
isoforms is to regulate the synthesis of their products, LPA and PA, as intracellular signaling 
molecules that can affect cellular processes in addition to PL and TAG synthesis [19].  LPA 
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 secreted into plasma by immune cells can bind to extracellular G-protein-coupled receptors 
(EDGE receptors) that are involved in the regulation of cell growth [73]. Additionally, 
intracellular LPA may activate transcription factors such as PPARγ [74]. PA can activate 
kinases in the Ras/Raf/ERK signaling pathway that regulates cellular differentiation and 
survival, and it may also activate survival pathways through activation of mTOR [71, 75].  
Additionally, the DAG product of phophatidic acid phosphohydrolases (Lipin), can activate 
conventional and novel forms of protein kinase C, which are involved in multiple cell 
signaling pathways (Parker, 2004). Traditionally, these signaling glycerolipids were thought 
to be generated from membrane phospholipids, not from de novo glycerolipid synthesis, but 
the increased association of PKC isoform activation and DAG accumulation in insulin 
resistant tissues whose TAG content is elevated suggests that intermediates of de novo 
triacylglyerol synthesis could be involved in activating intracellular signaling pathways. 
Further studies are necessary to identify the particular roles of GPAT and AGPAT isoforms 
in channeling acyl-CoAs to PL and TAG synthesis, as well as their potential roles in 
regulating intracellular signaling by LPA, PA, and DAG.  
 
2.7  Fatty Liver and the Metabolic Syndrome 
Once thought to be a benign hallmark of excessive alcohol consumption, hepatic 
triacylglycerol (TAG) accumulation has recently been acknowledged as a significant 
metabolic disorder. Non-alcoholic fatty liver disease (NAFLD) is associated with obesity, 
insulin resistance, type 2 diabetes, and cardiovascular disease [76-79].  Accumulation of 
TAG in hepatocytes is associated with increased very low density lipoprotein (VLDL) 
secretion from the liver, leading to high plasma TAG and cholesterol levels [79].   Elevated 
24 
 plasma lipids can induce TAG accumulation in extra-hepatic tissues, such as skeletal and 
heart muscle, and TAG accumulation in these tissues may contribute to the development of 
whole-body insulin resistance.  Although associations between insulin resistance and 
NAFLD are well documented, the role of hepatic steatosis in the development of whole-body 
and hepatic insulin resistance is not completely understood. 
 
2.7.1  The Role of Fatty Liver in Insulin Resistance: 
The pathogenesis of whole-body insulin resistance is complex, involving multiple 
organs and endocrine systems that are involved in the regulation of energy homeostasis.  
Four of the main organs affected by diabetes and insulin resistance include the liver, 
pancreas, adipose tissue, and skeletal muscle, and it has been hypothesized that alterations in 
the distribution of fat between adipose tissue, liver, and muscle are primarily responsible for 
causing insulin resistance [80]. Each of these tissues has a unique role in the maintaining 
glucose and lipid homeostasis, and insulin resistance in any one of these tissues has been 
shown to contribute to whole-body insulin resistance and type 2 diabetes [81, 82].  Liver-
specific insulin receptor knock-out mice exhibit severe insulin resistance and impaired 
glucose tolerance, while muscle-specific and adipose-specific insulin receptor knock-out 
mice have normal glucose tolerance, suggesting that the liver could play an important role in 
the pathogenesis of insulin resistance [81-83].  A recent study of glucose tolerance and 
insulin sensitivity in obese patients with normal glucose tolerance tests indicates that hepatic 
steatosis can increase insulin resistance independently of obesity [84].  In another study, 
patients with type 2 diabetes and hepatic steatosis were substantially more insulin resistant 
than those with type 2 diabetes and no hepatic steatosis [85], suggesting that liver fat 
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 accumulation can play a causal role in the development of insulin resistance and type 2 
diabetes in humans. 
 
Hepatic insulin resistance develops when the liver is less sensitive to the suppressive 
effects of insulin on hepatic glucose output (HGO) and VLDL TAG production. Hepatic 
steatosis and hepatic insulin resistance co-exist in many animal models, including, high-fat 
and high-sucrose diet-induced obesity in rats [86, 87], obese Zucker rats [88], leptin deficient 
mice [89], A-ZIP/F-1 fatless mice [90], CD36 fatty acid transporter KO mice [10], and 
ethanol fed rats [91].  Furthermore, hepatic steatosis in animal models is highly correlated 
with systemic insulin resistance [92]. Additionally, the amelioration of steatosis has been 
associated with increased insulin sensitivity.  A-ZIP/F1 transgenic fatless mice accumulate 
TAG in liver and muscle and are insulin resistant.  Hepatic and muscular steatosis and insulin 
resistance is ameliorated when adipose tissue from wild-type mice is transplanted into the A-
ZIP/F1 mice [90].  Administering a PPARα agonist to ob/ob mice increases β-oxidation, 
lowers hepatic TAG accumulation, and improves hepatic insulin sensitivity [93].   
 
Despite these correlations, there are models of steatosis where hepatic insulin 
resistance is not evident.  Buettner et al. (2004) recently demonstrated that rats fed a high fat 
diet for 6 weeks do not have hepatic insulin resistance, despite hepatic steatosis and mild 
whole-body insulin resistance [94].  In another model, PTEN, a lipid phosphatase that 
negatively regulates the insulin-stimulated PI3K/Akt pathway, was selectively knocked out 
in mouse liver.  PTEN-LKO mice have hepatic steatosis but have increased hepatic insulin 
sensitivity compared to wild-type mice [95, 96].  Mice fed a methionine-choline-deficient 
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 diet develop steatohepatitis, but they have lower blood glucose levels and increased hepatic 
insulin sensitivity compared to control-fed mice [97].  Additionally, treatment of insulin 
resistant, steatotic mice with PPARγ agonists such as rosiglitazone improves hepatic insulin 
sensitivity despite an increase in hepatic TAG accumulation [86].   
 
The reason for improved insulin sensitivity in some models of steatosis and for 
insulin resistance in others is not understood, but differences in the specific types of lipids 
that accumulate in tissues may explain the differences in insulin sensitivity.  Increased de 
novo lipogenesis will not only increase TAG synthesis, but will also increase the synthesis of 
other lipid metabolites, such as acyl-CoAs, LPA, PA, DAG, or ceramide that could 
accumulate in the liver and affect insulin sensitivity.  Another possibility is that hepatic 
steatosis caused by an increase in de novo glycerolipid synthesis is more likely to cause 
insulin resistance than steatosis caused by a reduction in secretion of TAG from the liver in 
VLDL particles.  In this case, lipid metabolites generated during the synthesis of TAG could 
act as signaling molecules that block insulin signaling.  TAG that accumulates in hepatocytes 
as a result of a block in TAG secretion would not increase lipid intermediates that could 
interfere with the insulin signaling pathway. 
 
2.8  Insulin signaling and insulin resistance  
Insulin is a peptide hormone that is secreted by pancreatic beta cells in response to 
elevated blood glucose levels during and following a meal.  Insulin binds to extracellular 
tyrosine kinase receptors on cells and initiates signaling cascades that mediate a variety of 
cellular processes involved in cellular metabolism, cell growth, and cell survival.  When 
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 insulin binds to the insulin receptor, the receptor's tyrosine kinase activity 
autophosphorylates the receptor at several tyrosine residues.  Activation of the insulin 
receptor leads to recruitment and activation of insulin receptor substrate-1 and -2 (IRS-1/2) 
(Figure 2.2).  IRS-1/2 can activate phosphatidylinostitol 3-kinase (PI3K), which converts the 
phospholipid phosphoinositol-4,5, bisphosphate (PIP2) to phosphoinositol-3,4,5-
trisphosphate (PIP3).  PIP3 attracts other kinases to the plasma membrane through their 
plextrin homology domains, which bind PIP3.  Insulin's regulation of glucose and lipid 
metabolism in hepatocytes is mediated through signaling pathways down-stream of PI3K 
[98].  Recent studies with IRS-2 KO mice suggest that signaling pathways down-stream of 
IRS-2 are primarily responsible for insulin's regulation of glycogen synthesis and 
gluconeogenesis [99].  Signaling downstream of IRS-2 leads to the phosphorylation of 
Akt/PKB, which then phosphorylates GSK3.  Akt/PKB-mediated phosphorylation of GSK3β 
inactivates GSK3β, and allows glycogen synthase to become dephosphorylated and 
activated.  Signaling down-stream of GSK-3 may also activate PEPCK gene expression, thus 
inhibiting gluconeogenesis [100].  Insulin also increases the expression of many lipogenic 
enzymes in liver through increased transcription of SREBP-1c, thus promoting FA and TAG 
synthesis.  Insulin's regulation of SREBP-1c is down-stream of IRS-1 [101, 102], but the 
details of this regulation pathway are not known.  
 
In response to elevated blood glucose levels, insulin acts on skeletal muscle cells and 
adipocytes to increase glucose uptake into cells through increased translocation of GLUT4 
glucose transporters to the plasma membrane.  In adipocytes, insulin signaling also results in 
increased lipogenesis and decreased lipolysis.  Insulin acts to increase glycogen synthesis in 
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 skeletal muscle, as well as in liver, and it also decreases the activity and expression of liver 
enzymes involved in gluconeogenesis. Therefore, the overall action of insulin is to increase 
glucose uptake into cells, to decrease hepatic glucose output, and to increase lipogenesis in 
adipose tissue and liver.  
 
2.8.1 Lipid mediators of insulin resistance   
 The frequent association of TAG accumulation with insulin resistance in liver and 
other tissues implies that either TAG itself, or some other lipid product synthesized in 
parallel with TAG may act as a mediator that antagonizes insulin signaling.  TAG can be 
synthesized from acyl-CoAs derived from de novo lipogenesis or from re-esterification of 
acyl-CoAs derived from plasma FFAs.  De novo synthesis of fatty acids occurs in the liver in 
response to a meal high in carbohydrate and in response to increased insulin stimulation of 
enzymes involved in FA synthesis.  An increase in de novo lipogenesis and glycerolipid 
synthesis results in increased production of several lipids that could affect hepatic insulin 
sensitivity, such as malonyl-CoA, ceramide, acyl-CoA, LPA, PA, DAG, or TAG. Of these, 
malonyl-CoA, ceramide, acyl-CoA, DAG, and TAG accumulation have been implicated in 
insulin resistance.   
 
 Malonyl-CoA is a potent inhibitor of CPT-1, the enzyme responsible for shuttling 
long-chain fatty acids into mitochondria for beta-oxidation.  Thus, an increase in de novo 
lipogenesis increases malonyl-CoA levels and results in lowered rates of beta-oxidation, 
encouraging synthesis and accumulation of lipids.  Adenoviral over-expression of malonyl-  
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Figure 2.2.  Basic insulin signaling pathways in hepatocytes affects lipid and glucose 
metabolism. Protein dependent kinase 1 (PDK-1), Protein kinase B (Akt/PKB), 
phosphoinositol 3-kinase (PI3K), insulin receptor substrate (IRS), glycogen synthase kinase 3 
(GSK3).  
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  CoA decarboxylase in the livers of rats fed a high fat diet decreased malonyl-CoA levels and  
protected rats against diet-induced insulin resistance and hepatic steatosis [103].   
 
 Ceramide can be synthesized from palmitoyl-CoA and serine by serine 
palmitoyltransferase (SPT). Since palmitoyl-CoA is the primary FA synthesized in de novo 
lipogenesis, ceramide could accumulate in hepatocytes as a result of increased de novo 
lipogenesis and decreased beta-oxidation.  Ceramide accumulation has been implicated in the 
pathogenesis of insulin resistance in several tissues, including skeletal muscle, pancreatic 
beta-cells, heart, adipose tissue, and liver [104-107]. Ceramide can inhibit insulin signaling 
through activation of PKCζ and/or protein phosphatase A2 [105].  
 
The flux of acyl-CoA in the liver is increased both in de novo lipogenesis and during 
increased FFA influx into the liver; this flux of acyl-CoA or FFA into the liver could affect 
insulin sensitivity [108]. Acyl-CoA accumulation in skeletal muscle and liver has also been 
associated with insulin resistance [109, 110].  
 
Glycerolipid synthesis is initiated by GPAT, and down-stream lipid products of this 
pathway include LPA, PA, DAG, and TAG (Figure 2).  Of these lipids, DAG accumulation 
has been implicated in insulin resistance.  DAG accumulation has been documented in 
several models of IR [88, 110], and increased DAG synthesis is thought to mediate inhibition 
of insulin signaling through activation of various PKC isoforms that can inhibit the activity 
of signaling molecules that are down-stream of PI3K [111].   
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 2.8.2  DAG synthesis, PKC, and insulin resistance: 
Diacylglycerol production is the primary step leading to activation and translocation 
of conventional and novel PKC isoforms, and there are 3 major pathways that can produce 
DAG: 1) Receptor-stimulation of phopholipase C (PLC) initiates the hydrolysis of inositol 
phospholipids (PI) to yield DAG and IP3. 2) Phospholipase D (PLD) hydrolyses 
phosphatidylcholine (PC) to PA, which is converted to DAG by phosphatidic acid 
phosphohydrolase (Lipin) 3) DAG can be made through de novo synthesis from the 
glycolytic intermediate glycerol -3-phosphate (G-3-P) via LPA and PA intermediates [112] 
(Figure 2.3). The de novo synthesis of DAG provides the major source of DAG in most 
cells, and the DAG synthesized from this pathway acts a precursor for TAG, 
phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine synthesis [113]. 
 
De novo synthesis of DAG from PA has been implicated in the hyperglycemia-
induced DAG formation in diabetic tissues [114-116].  DAG synthesized by hydrolysis of 
phospholipids on cellular membranes by PLC and PLD is associated with increased protein 
kinase C (PKC) activity.  DAG-mediated activation of PKC has been observed in insulin 
resistant tissues, and PKC activation has been implicated in the inhibition of insulin signaling 
on several levels [111, 117, 118]. Novel PKCε and δ have recently been implicated in insulin 
resistance in liver induced by high-fat feeding or lipid infusion [119, 120], and both isoforms 
are elevated in diabetic liver [121, 122].  
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Figure 2.3.  Diacylglycerol synthesis pathways. Diacylglycerol (DAG), triacylglycerol 
(TAG), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidic acid (PA).  a, 
phosphatidic acid phosphohydrolase; b, sphingomyelin synthase; c, phospholipase C; d, 
phospholipase D; f, triacylglycerol lipase; g, monoacylglycerol acyltransferase.  
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Figure 2.4.  DAG activates PKCε, which associates with the insulin receptor and inhibits 
insulin receptor kinase activity and subsequent activation of IRS-2.  DAG can also activate 
PKCδ, which inhibits IR activity. 
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2.8.2.1 Protein Kinase C (PKC) 
Protein kinase C (PKC) is a serine/threonine kinase family of isoenzymes that play a 
central role in a wide variety of cellular signaling pathways that affect multiple biological 
responses, including cell proliferation and differentiation, transmembrane ion transport, 
smooth muscle contraction, gene expression, and glucose and lipid metabolism [112].  PKC 
isoforms can be classified into 3 different subfamilies.  Conventional PKC isoforms (cPKC) -
-α, βI, βII, and γ -- are activated by diacylglycerol DAG in the presence of 
phosphatidylserine and calcium ions, and they can be activated by phorbol esters.  Novel 
PKC isoforms (nPKC) -- δ, ε, θ,η, µ -- are activated by DAG but do not require calcium for 
activation, while atypical isoforms -- λ,ζ-- do not require calcium or DAG for activation and 
cannot be activated by phorbol esters [123].  Activation of the cPKC and nPKC isoforms is 
thought to require recruitment to the plasma or nuclear membranes and interaction with 
DAG.  Receptor tyrosine kinases (such as the insulin receptor) mediate the production of 
DAG by recruitment of PLCγ (phospholipase C) to the membrane, while G-protein coupled 
receptors mediate production of DAG by recruiting PLCβ [123].  Optimum activation of all 
three subfamily members appears to require phosphorylation by phosphoinositide-dependent 
kinase 1 (PDK-1) at a conserved tyrosine in the activation loop [124].  PDK-1 is recruited to 
the plasma membrane by PIP3, the product of PI3K.  PKC isoform expression patterns vary 
by tissue, subcellular localization, and disease status, but very little is known about the 
functional differences of PKC isoforms [112]. Rat hepatocytes express PKCα, βII, δ, ε,  and 
ζ isoforms, while whole liver also expresses the PKC λ and θ isoforms [125-127].   
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 Alterations in PKC isoform expression and DAG content in various tissues, including 
liver, has been associated with insulin resistance and type 2 diabetes in humans and in animal 
models [112, 128].  PKC activation may down-regulate insulin-mediated glucose uptake in 
muscle and adipose tissue by decreasing autophosphorylation and tyrosine kinase activity of 
the insulin receptor, inactivation of glycogen synthase, inhibition of insulin-stimulated 
Akt/PKB activity, increasing insulin receptor degradation, and increasing phosphorylation of 
IRS [111]. 
 
2.8.2.2 Novel PKC Isoforms ε and δ  in Insulin Resistance 
Recent studies in skeletal muscle and liver from diabetic patients and animal models 
have suggested a role for novel PKC isoforms ε, θ, and δ in the inhibition of insulin 
signaling.  Increased PKC ε and θ activity was observed in Zucker diabetic rat soleus muscle 
[111], and PKCε expression was elevated in diabetic Psammomy gerbil muscle and liver 
[122].  Streptozotocin-induced diabetes in rats led to increased PKCε, α, and βII protein 
expression in liver membrane fractions, and feeding Sprague-Dawley rats a high-fat 
safflower diet for 3 days induced hepatic steatosis, decreased insulin-stimulated 
gluconeogenesis, and activated PKCε [14, 120, 121].  Hepatic steatosis may cause insulin 
resistance through lipid-mediated activation of PKCε, which directly inhibits insulin receptor 
β kinase activity and tyrosine phosphorylation of IRS-2 [129] (Figure 2.3). Increased PKCε 
activity has also been associated with elevated c-Jun amino terminal kinase 1 (JNK1) activity 
[120, 129].  JNK interferes with insulin signaling [130], and can be activated by TNFα and 
free fatty acids [126, 131], which have been implicated in the development of insulin 
resistance [132].  Hepatic knock-down of PKCε prevents high-fat-diet-induced hepatic 
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 insulin resistance in rats, suggesting that activation of PKCε is required for the mechanism of 
hepatic insulin resistance in this model [129]. 
 
In addition to the evidence supporting a role for PKCε activity in insulin resistance, 
several studies support a role for increased PKCδ activity in insulin resistant muscle and liver 
tissues.  Lipid/heparin infusion during a hyperinsulinemic-euglycemic clamp increases 
human and rat skeletal muscle DAG content and membrane associated PKCδ [117, 119, 
126].  This increase in PKCδ was associated with a decrease in the NFkB inhibitor IkBα, 
which is degraded when IKKB is activated.  Activation of NFkB, a transcription factor 
involved in the transcription of genes involved in inflammation, has been associated with 
insulin resistance and type 2 diabetes  [133, 134].  These studies suggest that PKCδ activity 
may play a role in the pathogenesis of liver insulin resistance induced by increased blood 
FFA levels. 
 
2.8.3  Ceramide Synthesis: 
  Ceramide is a sphingolipid that serves as a second messenger in signaling pathways 
affecting numerous cellular functions. Ceramide is generated by two major pathways 1) de 
novo synthesis from palmitoyl –CoA and serine via serine palmitoyl transferase (SPT) and 
ceramide synthase 2) from hydrolysis of sphingomyelin (SM) by one of the 
sphingomyelinases (SMase) [135] (Figure 2.5). Synthesis of ceramide by SPT is dependent 
upon cellular concentrations of palmitoyl-CoA and serine. Since palmitoyl-CoA is the 
primary FA synthesized in de novo lipogenesis, ceramide could accumulate in hepatocytes as 
a result of increased de novo lipogenesis and decreased beta-oxidation.  Increased SPT 
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 activity in the liver is accompanied by increased fatty acid, TAG, and cholesterol synthesis 
[136].  Inhibition of CPT-I in cells treated with exogenous palmitate led to increased 
ceramide synthesis [137, 138]. Thus, alterations in the flux of palmitoyl-CoA towards 
oxidation pathways can affect ceramide production.  The preferred substrate of GPAT is 
palmitoyl-CoA, and increased GPAT activity channels fatty acids away from CPT-1 [37].  
Thus, over-expression of GPAT in rat liver could lead to increased ceramide production 
parallel to increased TAG synthesis if channeling of fatty acids away from CPT-1 increases 
palmitoyl-CoA availability for GPAT and SPT (Figure 2.6).  On the other hand, increased 
GPAT activity could channel palmitoyl-CoA away from SPT and CPT-1, resulting in 
decreased ceramide synthesis (Figure 2.7).  
 
2.8.3.1 Ceramide, PKC, PP2A, and Insulin Resistance 
Several mechanisms of ceramide action have been proposed for the reduction in 
insulin signaling in tissues that accumulate ceramide.  One mechanism involves the 
activation of various PKC isoforms by ceramide and subsequent phosphorylation and 
inactivation of members of the insulin signaling pathway. Ceramide decreases insulin-
stimulated Akt/PKB translocation to the plasma membrane in 3T3-L1 adipocytes and L6 
myotubes, thus preventing insulin stimulated glucose uptake [139, 140]. Also, a number of 
studies have demonstrated that PKCζ can interact with Akt/PKB and inhibit its activity [141, 
142].  Recently, Powell et al. (2003) found that ceramide-induced activation of PKCζ in L6 
myotubes prevented insulin stimulated PI3K activation of Akt/PKB, and that treatment of the 
cells with palmitate could induce ceramide accumulation, and PKCζ inhibition of Akt/PKB 
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Figure 2.5.  Ceramide synthesis.  Serine palmitoyl-CoA transferase (SPT), glucosylceramide 
synthase (GC Synth), sphingomyelinase (SMase), sphingomyelin synthase (SM Synth), 
ceramide synthase, sphingosine kinase (SphK).  
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Figure 2.6.  Over-expression of GPAT1 could increase the availability of palmitoyl-CoA for 
de novo ceramide synthesis and for glycerolipid synthesis by increasing the demand for de 
novo lipogenesis of fatty acids. Increased de novo lipogenesis leads to increased synthesis of 
mal-CoA and inhibition of CPT-1.  Malonyl-CoA (Mal-CoA), carnitine palmitoyl 
transferase-1 (CPT-1), glycerol-3-phosphate acyltransferase (GPAT), serine palmitoyl 
transferase (SPT). 
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Figure 2.7.  Over-expression of mtGPAT could decrease the availability of palmitoyl-CoA 
for de novo ceramide synthesis by partitioning palmitoyl-CoA towards glycerolipid synthesis 
and away from oxidation.  Malonyl-CoA (Mal-CoA), carnitine palmitoyl transferase-1 (CPT-
1), glycerol-3-phosphate acyltransferase (GPAT), serine palmitoyl transferase (SPT). 
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 activity [143, 144].   These studies implicate ceramide and PKCζ in fatty acid-induced 
insulin resistance in skeletal muscle cells.  The second mechanism proposed involves 
ceramide activation of protein phosphatase 2A (PP2A).  PP2A has been shown to 
dephosphorylate Akt/PKB as a result of ceramide treatment of 3T3-L1 adipocytes [105].  
Stratford et al. (2004) recently proposed that ceramide acts to prevent Akt/PKB activation 
using both mechanisms [105] (Figure 2.8).  
 
2.8.3  Immune Mediators of Insulin Resistance   
Obesity is associated with insulin resistance and fatty liver, and there is evidence for 
low-grade chronic systemic inflammation in patients with these disorders [145-147].  The 
development of obesity is associated with an increased infiltration of macrophages from the 
bone marrow into adipose tissue and other tissues [148].  When activated, macrophages 
produce a variety of cytokines, including TNFα, IL-6, and IL-1, and adipocytes may also 
contribute to cytokine production in obese patients [149, 150].  Increased circulating levels of 
these cytokines can cause insulin resistance, and anti-inflammatory treatments may reduce its 
severity [149, 151-155].   
 
2.8.3.1 NF-kappa B 
NFκB is one of the most important transcription factors that regulates inflammatory 
genes, and activates NFκB has been implicated in numerous immune-mediated diseases, 
including atherosclerosis, asthma, cancer, alcoholic liver disease, and rheumatoid arthritis 
[156].  The evidence that NFκB plays a critical role in the pathogenesis of insulin resistance 
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Figure 2.8.  Ceramide activates PKCζ and/or PP2A, which prevents Akt/PKB translocation 
and phosphorylation. 
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is significant.  Treatment of diabetics with high doses of salicylates inhibits NFκB and 
dampens inflammation and reduces blood glucose levels [157-159].  Chronic hyperglycemia 
activates NFκB in endothelial cells [160, 161], and both genetic obesity and high-fat-diet-
induced obesity increase hepatic NFκB expression and expression of NFκB- regulated 
cytokines [133].  In liver, NFκB controls the expression of multiple inflammatory mediators, 
including CRP, PAI-1, IL-6, TNFα, and IL-1 [133].  TNFα and IL-6 can cause hepatic 
insulin resistance, and elevated plasma concentrations of CRP are common in obesity and 
insulin resistance [162].  IL-1β has been implicated in the suppression of insulin-mediated 
hepatic glycogen synthesis [163].  NFκB is activated when inhibitory-kappa B kinase (IKK-
β) phosphorylates and inactivates the inhibitor of NFκB, IκB.  Inhibition of IKK-β improves 
insulin resistance in mice, and liver specific activation of NFκB in mice causes systemic 
insulin resistance that can be inhibited by treatment with anti-IL-6 antibodies or salicylates 
[133, 152, 164].  Together, these studies suggest a prominent role for NFκB activation in the 
pathogenesis of both hepatic and systemic insulin resistance. 
 
2.8.3.2  TNFα 
TNFα and IL-6 are elevated in the plasma of type 2 diabetics [165-167], and can 
mediate hepatic insulin resistance [149, 168, 169].  TNFα production by adipocytes and 
macrophages is elevated in numerous animal models of diabetes, and TNFα action in 
adipocytes results in increased lipolysis and plasma FFA levels[170].  Plasma TAG is also 
increased by TNFα, which may be due to TNFα-mediated inhibition of lipoprotein lipase  
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Figure 2.9.  TNFα signaling activates SMase to generate ceramide.  Ceramide can activate 
PKCζ or PPA2 to inhibit Akt/PKB activation.  TNFα can also activate JNK-1, which down 
regulates IRS activation by the insulin receptor.   
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Figure 2.10.  Activation of the IL-6 receptor leads to activation of STAT-3 and SOCS-3.  
SOCS-3 can inhibit tyrosine phosphorylation and activation of the insulin receptor. 
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 expression in adipocytes [151]. Prolonged infusion of TNFα in rats impairs both insulin-
mediated whole-body glucose disposal and insulin-stimulated hepatic glucose output [151].   
 
In liver, resident macrophages called Kupffer cells, and infiltrating macrophages are 
activated when hepatocytes are injured or stressed. Kupffer cells are the main source of 
TNFα in the liver [171].  TNFα signaling in hepatocytes can activate inhibitory-κB kinase-
beta (IKKβ), which degrades the inhibitor of NFκB, IκB, allowing NFκB translocation to the 
nucleus and activation of NFκB-regulated genes [133, 172].  NFκB induces the transcription 
of IL-6, which increases the activation of SOCS proteins, which are feedback regulators of 
cytokine signaling.  Activation of SOCS can inhibit insulin signaling through IRS-2 because 
SOCS-1 directly inhibits IRS-2, and SOCS-3 competes with IRS-2 for docking sites on other 
proteins [169, 173] (Figure 2.10).  Additionally, both SOCS-1 and -3 can ubiquinate IRS-2 
[173].  TNFα signaling can also activate JNK-1, which can inactivate IRS-2 via serine 
phosphorylation, and TNFα may contribute to ceramide-mediated insulin resistance through 
activation of SMase [151, 170, 174] (Figure 2.9).   
 
The importance of TNFα signaling in the liver was demonstrated recently in several 
mouse models.  Mice deficient in TNFα-receptors were protected from hepatic steatosis and 
ob/ob mice treated with anti-TNFα antibodies had reduced hepatic steatosis that was 
associated with reduced IKKβ activity and increased insulin sensitivity [154, 175, 176]. Mice 
deficient in TNFα (TNFα-/- mice) and wild-type mice (TNFα+/+ mice) were irradiated and had 
bone marrow transplants with either wild-type (WT) or TNFα deficient (KO) bone marrow.   
The mice were fed high-fat diets for 26 weeks.  TNFα-/-/bone marrow KO mice were 
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 protected from diet-induced hepatic steatosis and hepatic insulin resistance, while all four 
other treatment groups developed steatosis and insulin resistance [150].  Thus, TNFα 
signaling in hepatocytes may increase hepatic fat accumulation and contribute to hepatic 
insulin resistance. 
 
2.8.3.3  Interleukin-6 
Adipose tissue produces one third of the circulating plasma IL-6, and an increase in 
plasma IL-6 concentrations is associated with obesity and type 2 diabetes [174].  In 
hepatocytes, IL-6 inhibits insulin signaling through activation of SOCS proteins [168, 169, 
173, 174].   Chronic treatment of mice with IL-6 causes insulin resistance, and when insulin 
resistant ob/ob mice are injected with anti-IL-6 antibodies, hepatic insulin sensitivity is 
dramatically improved, while adipocyte and muscle insulin sensitivity are not altered [155, 
177].  These studies suggest that circulating IL-6 can impair hepatic insulin sensitivity, and 
that IL-6 released from adipocytes or macrophages during the development of obesity could 
contribute to hepatic insulin resistance. 
 
2.9  GPAT1, TAG Synthesis, and Insulin Resistance:   
Mice lacking a functional copy of GPAT1 (GPAT1-/-) are resistant to high-fat-diet 
and high-fat/high-sucrose-diet-induced hepatic steatosis, with a reduction in hepatic TAG 
levels and in serum TAG concentration [13, 14].  Liver LPA and DAG content is reduced 2-
fold in GPAT1-/- mice, while liver acyl-CoA content and serum beta-hydroxybuterate are 
elevated 2-fold, suggesting a shift from glycerolipid synthesis to β-oxidation [13, 14].  Mice 
are protected from high-fat-diet-induced insulin resistance when fatty acid oxidation is 
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 increased and hepatic lipid accumulation is decreased, so mice deficient in GPAT1 might be 
expected to be more insulin sensitive than wild-type mice (Ide, 2004).  However, the effect of 
a reduction in GPAT1 activity on the insulin sensitivity of mice fed high-fat diets is not clear.  
GPAT1-/- mice fed a high fat/high sucrose (HH) diet for 4 months were less insulin sensitive 
than their wild-type counterparts, despite a 50% lower hepatic TAG content and an increased 
rate of fatty acid oxidation [13].  However in high-fat safflower oil fed GPAT1-/- mice, a 
reduction in hepatic DAG and TAG synthesis and an increase in fatty acid oxidation has 
positive effects on whole body lipid homeostasis and on insulin sensitivity [14]. GPAT1-/- 
mice were protected from high-fat diet induced insulin resistance as shown by 
hyperinsulinemic euglycemic clamp procedures.  The glucose infusion rate required to 
maintain constant blood glucose levels was 33% higher in the GPAT-/- mice compared to 
wild-type.  Additionally, hepatic glucose production was suppressed by 80% in GPAT1-/- 
mice compared to only 20% in wild-type mice.  These results suggest that GPAT1-/- mice 
have increased hepatic insulin sensitivity and that they are protected from high-fat induced 
insulin resistance [14].  Improved hepatic insulin sensitivity was associated with reduced 
hepatic DAG content and reduced PKCε activity, which may have led to reductions in IRS2 
associated PI3K and Akt2 activities [14].   
 
The reasons for the differences in the insulin sensitivity of GPAT1-/- mice on the HH 
and high-fat safflower oil diets are not clear, because hepatic TAG content was lower in 
GPAT1-/- mice on both diets.  Additionally, hepatic acyl-CoA content was elevated in 
GPAT1-/- mice fed both diets, and there were no obvious differences in plasma lipid profiles.  
Differences in dietary lipid and sucrose content could explain the conflicting effect of these 
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 two diets on hepatic insulin sensitivity in GPAT1-/- mice.  The HH diet was high in medium 
chain fatty acids, whereas the safflower oil diet is particularly high in linoleic acid.  Although 
hepatic acyl-CoA content was elevated in GPAT1-/- mice fed both diets, oleoyl-CoA was the 
predominant species in mice fed the HH diet, whereas linoleoyl-CoA was the predominant 
species in mice fed the safflower oil diet.  It is not clear why the accumulation of a particular 
acyl-CoA species would cause insulin resistance, but it is possible that a particular species 
could act as a signaling molecule that affects insulin signaling pathways. Another difference 
between the two diets was the high sucrose in the HH diet.  Because there was no high 
sucrose control group, it is difficult to know how this dietary difference may contribute to the 
insulin resistance in the HH-fed GPAT1-/- mice.  The final difference between the two studies 
is the duration of high-fat feeding.  In the HH study, mice were fed the HH diet for 4 months, 
and in the safflower oil study the mice were fed the high-fat diet for 3 weeks.  It is possible 
that chronic exposure to a high-fat diet is more detrimental in GPAT1-/- mice due to increased 
production of hepatic lipid peroxides, which could activate immune-mediated insulin 
resistance pathways in the liver [178].   
 
Although ceramide content of the livers from GPAT1-/- mice on either diet was not 
measured, it is possible that the differences in fatty acid composition of the high fat diets 
contributed to different levels of ceramide accumulation in the GPAT1-/- mice.  A recent 
publication has shown that rats infused with soybean oil, which is high in linoleic acid, and 
those infused with lard oil, which is high in palmitic acid, had different mechanisms of 
hepatic insulin resistance [104].  The insulin resistance in rats infused with linoleate was 
attributed to DAG, while the insulin resistance in rats infused with palmitic acid was 
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 associated with ceramide, despite concurrent accumulation of DAG [104].  Thus, it is 
possible that GPAT1-/- mice were protected from hepatic insulin resistance on the high-fat 
safflower oil diet because DAG accumulation was reduced, and ceramide did not accumulate 
due to the low level of palmitate in the diet.  However, GPAT1-/- mice fed the HH diet were 
not protected from hepatic insulin resistance because the high saturated fat/high sucrose diet 
provided palmitate from dietary fatty acids and from de novo lipogenesis that could be used 
for ceramide synthesis instead of glyceorlipid synthesis (blocked due to knock-out of 
GPAT1) and instead of β-oxidation (overloaded due to lack of GPAT1 and influx of FFA 
from high fat diet).   
 
Studies of insulin sensitivity in GPAT1-/- mice suggest that alterations in the systemic 
expression and activity of GPAT1 can alter hepatic insulin sensitivity, possibly through 
changes in hepatic lipid content.  However, it is not clear whether GPAT1 deficiency in 
hepatocytes is responsible for the changes in insulin sensitivity, or whether GPAT1 
deficiency in adipose tissue, pancreas, skeletal muscle, or immune cells could also be 
contributing to increased insulin sensitivity in these mice.  There was evidence for increased 
insulin sensitivity in adipose tissue of GPAT1-/- mice fed the high-fat safflower oil diet, 
suggesting that the decrease in liver lipid levels was not the only factor responsible for 
protecting the mice from hepatic and systemic insulin resistance [14].  The specific role of 
liver glycerolipid accumulation in the pathogenesis of hepatic and systemic insulin resistance 
is not known. 
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CHAPTER III  HEPATIC OVEREXPRESSION OF GPAT1 
 
 
Although fatty liver is associated with insulin resistance, and the amelioration of fatty 
liver in insulin resistant animals is associated with improved insulin sensitivity in many 
animal models, it is still unclear whether liver triglyceride accumulation plays a causal role in 
whole body insulin resistance.  Most existing animal models of fatty liver and insulin 
resistance have been created through high-fat or high-sucrose feeding or through genetic 
disruption of insulin or leptin signaling pathways.  High-fat or high-sucrose diet-induced 
fatty liver and insulin resistance is not a good model for studying the role of the liver in the 
pathogenesis of IR, since these diets induce obesity, which, in itself, is a risk factor for IR. 
Whole-body deficiencies in leptin or insulin signaling also cause obesity in mice due to 
reduced satiety and increased feeding behavior.  Since adipose tissue is thought to contribute 
to whole-body insulin resistance, it is not possible to isolate the role of the liver in the 
pathogenesis of IR in mouse models of obesity.   
 
To examine the roles of hepatic triglyceride accumulation and increased de novo glycerolipid 
synthesis in the pathogenesis of whole-body and hepatic insulin resistance, we infected rats 
with an adenovirus that expresses GPAT1 (Ad-GPAT1) to overexpress GPAT1 in the liver of 
rats.  Since GPAT1 is a key regulatory enzyme in the de novo triglyceride synthesis pathway, 
we expected to induce fatty liver without the need to feed high-fat or high-sucrose diets to the 
 rats.  Since GPAT1 expression is regulated by SREBP-1c, and livers of insulin resistant 
animals have increased SREBP-1c expression, hepatic over-expression of GPAT is a realistic 
model for the hepatic steatosis observed in insulin-resistant animals.  Additionally, by 
targeting GPAT1 overexpression to the liver, we have ensured that the primary site of 
metabolic dysfunction is in the liver. 
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 3.1 ABSTRACT:  
Fatty liver is commonly associated with insulin resistance and type 2 diabetes, but it is 
unclear whether triacylglycerol accumulation or an excess flux of lipid intermediates in the pathway 
of TAG synthesis are sufficient to cause insulin resistance in the absence of genetic or diet-induced 
obesity.  To determine whether increased glycerolipid flux can, by itself, cause hepatic insulin 
resistance, we used an adenoviral construct to overexpress glycerol-sn-3-phosphate acyltransferase-1 
(Ad-GPAT1), the committed step in de novo triacylglycerol synthesis.  After 5-7 days, food intake, 
body weight, and fat pad weight did not differ between Ad-GPAT1 and Ad-EGFP control rats, but the 
chow-fed Ad-GPAT1 rats developed a fatty liver, hyperlipidemia and insulin resistance.  Liver was 
the predominant site of insulin resistance; Ad-GPAT1 rats had 2.5-fold higher hepatic glucose output 
than controls during a hyperinsulinemic-euglycemic clamp.  Hepatic diacylglycerol and 
lysophosphatidate were elevated in Ad-GPAT1 rats, suggesting a role for these lipid metabolites in 
the development of hepatic insulin resistance, and hepatic PKCε was activated, providing a potential 
mechanism for insulin resistance.  Ad-GPAT1-treated rats had 50% lower hepatic NF-κB activity and 
no difference in expression of TNF-α and IL-β, consistent with hepatic insulin resistance in the 
absence of increased hepatic inflammation.  Glycogen synthesis and uptake of 2-deoxyglucose were 
reduced in skeletal muscle, suggesting mild peripheral insulin resistance associated with a higher 
content of skeletal muscle triacylglycerol.. These results indicate that increased flux through the 
pathway of hepatic de novo triacylglycerol synthesis can cause hepatic and systemic insulin resistance 
in the absence of obesity or a lipogenic diet.   
 
3.2 INTRODUCTION: 
Hepatic steatosis, an increasingly common health concern, is associated with obesity, insulin 
resistance, type 2 diabetes, and cardiovascular disease [179-182].  Despite the association of hepatic 
steatosis with insulin resistance, and the amelioration of hepatic triacylglycerol accumulation with 
improved insulin sensitivity, it is still unclear whether insulin resistance causes the increase in hepatic 
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 triacylglycerol or whether the increase in glycerolipid intermediates or triacylglycerol itself plays a 
causal role in hepatic or systemic insulin resistance [6-12].  Most animal models of hepatic steatosis 
and insulin resistance have been created through high-fat or high-sucrose feeding or through genetic 
disruption of insulin or leptin signaling pathways.  Diet-induced hepatic steatosis, however, is not a 
good model for isolating the role of the liver in the pathogenesis of insulin resistance because high-fat 
diets cause weight gain and obesity, which independently contribute to the development of systemic 
insulin resistance.  Systemic deficiencies in leptin or insulin signaling also cause obesity by 
increasing centrally-mediated food intake.  An animal model that isolates the accumulation of 
triacylglycerol in liver from its accumulation in other tissues may provide a better understanding of 
the role of hepatic lipid synthesis or accumulation in the development of hepatic and peripheral 
insulin resistance. 
 
Acyl-CoA:glycerol-3-phosphate acyltransferase (GPAT) is the committed step in the de novo 
synthesis of TAG and glycerophospholipids [29].  GPAT esterifies fatty acids to glycerol-3-phosphate 
at the sn-1 position, forming lysophosphatidic acid (LPA) (Figure 3.1).  Three different isoenzymes of 
GPAT have been described, one located in the endoplasmic reticulum (GPAT3), and two located in 
the outer mitochondrial membrane (GPAT1 and GPAT2) [3, 5, 26, 183].  Only GPAT1 and GPAT2 
have been cloned.  GPAT2 and GPAT3 activities are sensitive to N-ethylmaleimide (NEM), whereas 
GPAT1 is not.  GPAT1 activity accounts for 30-50% of total liver GPAT activity, but is only 10% of 
total GPAT activity in other tissues [29].  Unlike GPAT2 and 3, GPAT1 is transcriptionally regulated 
by carbohydrate re-feeding via carbohydrate-responsive elements and by insulin via SREBP-1c, 
suggesting that glycerolipid metabolism can be regulated through changes in GPAT1 expression in 
response to altered nutrient availability [41, 47, 49].   
 
Recent studies in primary hepatocytes demonstrated that overexpression of GPAT1 primarily 
directs exogenous fatty acids away from β-oxidation and toward DAG and TAG rather than  
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Figure 3.1: Pathway of de novo glycerolipid synthesis.  GPAT isoforms located in mitochondria 
(GPAT1) and endoplasmic reticulum (GPAT3) catalyze the initial step in the synthesis of 
triacylglycerol (TAG).  Acyl-CoA use for β-oxidation or TAG synthesis is regulated reciprocally by 
carnitine palmitoyl transferase-1 (CPT-1) and GPAT1.  Lysophosphatidic acid (LPA), phosphatidic 
acid (PA), and diacylglycerol (DAG), triacylglycerol (TAG), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), and fatty acid (FA). 
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phospholipid synthesis. [36, 37].  Conversely, when GPAT1 is absent, mice are protected from high-
fat-diet-induced hepatic steatosis and insulin resistance [2, 14].  These studies suggest that GPAT1 
plays an important role in the regulation of hepatic TAG accumulation, and that the synthesis of this 
TAG pool can affect hepatic insulin sensitivity.   
 
To determine whether an increase in hepatic TAG and the synthesis of its glycerolipid 
precursors leads to hepatic and systemic insulin resistance in the absence of obesity, we targeted the 
overexpression of GPAT1 to the liver using an adenoviral-GPAT1 construct (Ad-GPAT1).  Because 
GPAT1 is a key enzyme in the pathway of de novo TAG synthesis, we expected to induce hepatic 
steatosis without the need to feed a lipogenic diet.  Also, because GPAT1 specific activity is elevated 
in livers from mice with diet-induced obesity and from ob/ob mice with leptin-deficiency, 
overexpression of GPAT1 is a realistic model for the hepatic steatosis observed in insulin resistant 
animals [36].  The accumulation or increased flux of lipid metabolites in the glycerolipid synthetic 
pathway, including acyl-CoAs, LPA, and DAG, have been implicated in the development of insulin 
resistance [118, 184-189].  We hypothesized that hepatic overexpression of GPAT1 would cause both 
lipid metabolites and TAG to accumulate and increase hepatic insulin resistance in the absence of 
obesity or high-fat feeding.  
 
3.3 METHODS 
Recombinant adenoviruses.  The construction and generation of recombinant GPAT1-Flag 
adenovirus and Ad-EGFP have been described previously [37].  These viruses were plaque purified 
and then further amplified and purified for injection into rats by previously described methods [103, 
190]. 
 
Animal experiments.  All procedures involving animals were approved by the Duke University or 
Vanderbilt University Institutional Animal Care and Use Committees.  Male Wistar rats (300-350 g; 
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 Charles River) were housed in individual cages with a 12 hour light cycle and given free access to 
standard chow (Harlan Teklad 7001, Harlan Teklad Laboratories).  Rats received a single dose (1.0 x 
1012 or 2.0 x 1012 particles/mL per 300 g body weight) of Ad-GPAT1 or Ad-EGFP adenoviruses by 
tail-vein injection.  Rats were given a dose (15 mg/kg body weight) of cyclosporine the day before 
and the day of the virus administration to minimize the immune response.  Food consumption and 
body weight were monitored daily.  Five to 7 days after virus injection, food was withdrawn 4 h 
before collection of blood by heart puncture of anesthetized animals.  Tissues were collected by 
clamp freezing and stored at -80º C. 
 
Hyperinsulinemic-euglycemic clamp experiments.  Hyperinsulinemic-euglycemic clamp studies 
were performed as described previously with the following modifications (32).  Male Wistar rats (300 
g body weight) were anesthetized with sodium pentobarbital (50 mg/kg), and catheters were 
implanted in the carotid artery, external jugular vein, and ileal vein.  After surgery, the rats recovered 
for 2 wk, then, Ad-GPAT1 or Ad-EGFP virus was injected through the tail vein at 1.0-2.0 x 1012 
particles/mL 7 d before the clamp study.  At -150 min a bolus of [3-3H] glucose (15 µ Ci/kg) was 
administered followed by a constant infusion of labeled glucose (0.15 µCi/kg/min).  Somatostatin was 
infused at 3 µg/kg/min, and glucagon and insulin were infused at 2.6 ng/kg/min and 3 mU/kg/min, 
respectively, to maintain plasma glucagon and insulin levels at ~ 40 pg/mL (arterial plasma) and ~3 
ng/mL (arterial plasma), respectively.  2-deoxy-[14C]-glucose (50 µCi/rat) was administered through 
the carotid arterial catheter at 120 min during the clamp.  During the clamp, blood glucose was 
monitored every 10 min via carotid arterial catheter samples  Plasma glucose, [3H]H2O, [3-3H] 
glucose, and 2-deoxy-[14C]-glucose were measured to determine glucose disposal rate, hepatic 
glucose output, and the glycolytic rate.  Liver and skeletal muscle glycogen content and 
[3H]radioactivity in glycogen was measured to analyze glycogen synthesis.  Skeletal muscle 2-deoxy-
[14C]-glucose-6-phosphatase was measured to determine glucose uptake. 
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 Measurement of plasma metabolic variables.  Plasma TAG concentrations were measured using an 
enzymatic colorimetric assay kit (Stanbio Laboratory).  Plasma cholesterol levels were measured 
using the Cholesterol CII kit (Wako Chemicals).  Plasma alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), glucose, and β-hydroxybutyrate concentrations were measured using kits 
from Stanbio Laboratory.  Fatty acid concentrations were measured using a kit from Roche.  Plasma 
insulin and leptin levels were measured by radioimmunoassay (Linco).  Very low density and high 
density plasma lipoprotein fractions were isolated from 100 µL total plasma using fast protein liquid 
chromatography with a Superose 6 HR10/30 column (Pharmacia Biotech Inc).  Triglyceride and 
cholesterol contents of plasma fractions were determined using the colorimetric kits described above. 
 
Membrane isolation and measurement of GPAT1 activity.  Liver tissue was homogenized in 
Medium I (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, and 1 mM DTT) with 10 up-and-
down strokes in a Teflon-glass motor-driven homogenizer.  Homogenates were centrifuged at 
100,000 x g for 1h to obtain the total membrane fraction.  The membrane pellet was re-homogenized 
in Medium I and stored in 100 µL aliquots at -80º C for the enzyme assay.  GPAT1 specific activity 
was assayed at RT in a 200 µL reaction mixture containing 75 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 1 
mg/mL bovine serum albumin (essentially FA-free), 1 mM DTT, 8 mM NaF, 800 µM [3H]glycerol-3-
phosphate, and 80 µM palmitoyl-CoA [183].  The reaction was initiated by adding 10-30 µg of total 
membrane protein to the assay mix after incubating the membrane protein on ice for 15 min in the 
presence or absence of 1 mM NEM.  GPAT1 activity is calculated as the activity that is uninhibited 
by NEM. 
 
Western blot.  GPAT1-FLAG and EGFP expression were determined in liver (and muscle) total 
particulate fractions by Western blot using a mouse monoclonal anti-FLAG antibody (Clone M2, 
Sigma) and a monoclonal anti-EGFP antibody (ab3277, Abcam Inc.).  PEPCK protein expression was 
determined in rat liver samples using a rabbit polyclonal anti-PEPCK (Santa Cruz) antibody. 
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Tissue triglyceride and glycogen content.  Liver, muscle, or heart tissue (100 mg) was homogenized 
in water and lipids were extracted into CHCl3 [191] dried in a SpeedVac and resuspended in 1 mL 
CHCl3.  A fraction of the original lipid extract (50 µL for liver and 200 µL for heart or muscle) was 
dried and resuspended in 100 µL isopropanol, 1% Triton X-100 at room temperature for 1 h.  The 
TAG content of 10-30 µL of the lipid sample was determined using an enzymatic colorimetric 
method (Stanbio Laboratory).  Liver glycogen content was measured using an amyloglycosidase-
based assay [192]. 
 
Mass spectrometric analysis of liver lipid contents.  The extraction procedures for acyl-CoA, LPA, 
and DAG species were performed as described previously [14].  To extract acyl-CoA, approximately 
100 mg of liver was homogenized with a 17:0-CoA internal standard.  Acyl-CoAs were purified using 
Oligonucleotide Purification Cartridges (Applied Biosystems) and were slowly eluted with 60% 
acetonitrile.  For LPA measurements, approximately 100 mg of liver was homogenized in 
chloroform/methanol (1:1; v/v) with 1 nM C17:0-lysophosphatidic acid as the internal standard.  
Samples were homogenized and centrifuged twice, each time with chloroform/methanol (1:1; v/v).  
The supernatants were combined and mixed with dH2O to obtain an aqueous phase.  The aqueous 
phase was then mixed with dH2O and applied to conditioned Waters Oasis MAX extraction cartridges 
(Waters Corporations).  After a washing step, LPA and phosphatidic acid species were eluted with 
methanol for LC/MS/MS analysis.  Different LPA species were separated with an HPLC Betasil C18 
Dash HTS column (Thermo Electron Corporation) using varying gradients of solutions A (95 % 
dH2O, 5 % acetonitrile, 2 mM ammonium acetate) and B (95% acetonitrile, 5% dH2O, 2 mM 
ammonium acetate). 
 
 For DAG, approximately 100 mg of liver tissue was homogenized in ice-cold 
CHCl3/methanol (2:1; v/v) containing 0.01% butylated hydroxytoluene and the internal standards 1,3-
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 dipentadecanoin and 1,2,3-triheptadecanoate.  Organic and aqueous phases were separated by adding 
CHCl3 and H2O.  After centrifugation, the organic layer was collected, dried under nitrogen flow, and 
reconstituted with hexane/methylene chloride/ether (89/10/1; v/v).  DAG was separated from TAG 
with preconditioned columns (Waters Sep Pak Cartridge WAT020845) and eluted with hexane/ethyl 
acetate (85/15, v/v) under a low negative pressure. 
 
 Lipid metabolite extracts were subjected to LC/MS/MS analysis.  A turbo ionspray source 
was interfaced with an API 3000 tandem mass spectrometer (Applied Biosystems) in conjunction 
with two Perkin Elmer 200 Series micro pumps and a 200 Series autosampler (Perkin Elmer).  Total 
acyl-CoA, LPA, phosphatidic acid, and DAG content were expressed as the sum of individual 
species. 
 
Quantitative RT-PCR.  RNA was extracted from 0.02 g of frozen liver tissue using the RNeasy 
Mini spin column kit (Qiagen Inc) in combination with DNase digest treatment.  Quantitative real-
time reverse transcriptase PCR for IL-1β, PEPCK, G6Pase, and TNF-α were performed using an ABI 
PRISM 7500 Sequence Detection System instrument and Taq-Man® Universal PCR Master Mix 
(Applied Biosystems, Inc.) with Invitrogen MML-V reverse transcriptase.  Reactions were performed 
in triplicate.  Target gene expression was normalized to β-actin expression.  All data were quantified 
using the relative standard curve method as described in Applied Biosystems User Bulletin No.  2 
(P/N 4303859). 
 
NF-κB activity.  Liver (100 mg) was homogenized in 400 µL Dignam A Buffer (10 mM HEPES pH 
7.5, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, Sigma Protease Inhibitor Cocktail 100 µL /10 mL 
buffer) in a glass Dounce homogenizer.  Homogenates were left on ice for 20 min, then 40 µL of 10% 
NP-40 was added, and homogenates were vortexed for 15 s.  Cytoplasmic extracts were collected 
after the homogenates were centrifuged at 4500 x g for 3 min at 4º C.  The pellets were washed twice 
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 in Dignam A Buffer.  Nuclear membranes were disrupted with 100 µL of Dignam C Buffer (10 mM 
HEPES pH 7.5, 25 % glycerol, 420 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.5 mM DTT, and 
Sigma Protease Inhibitor Cocktail 100 µL/10 mL buffer) on ice for 15 min.  Nuclear extracts were 
collected after centrifugation at 14,000 rpm for 5 min to pellet the DNA.  NF-κB binding activity was 
determined using the TransAMTM NF-κB p65 Transcription Factor Assay ELISA kit (Active Motif).  
25 µg of liver nuclear extract was used in each well.   
 
PKCε activity.  PKCε membrane translocation assays were performed according to methods 
previously described (Qu et al., 1999; Donnelly et al., 1994).  Briefly, 50 µg of crude membrane and 
cytosol protein extracts were resolved by SDS-PAGE using an 8 % gel and electrotransferred onto 
PVDF.  Membranes were immunoblotted with a rabbit anti-peptide antibody against PKCε (Santa 
Cruz Biotechnology), diluted 1:100 in rinsing solution.  PKCε translocation was expressed as the 
ratio of arbitrary units of membrane bands over cytosol bands.  Protein bands were quantified using a 
Bio-Rad Chemidoc SRX and Quantity One Software (BioRad).   
 
Statistics -- Data were analyzed by Student’s t test or Kruskal-Wallis ANOVA with Dunn multiple 
comparison post-test.  Data are shown as mean ± S.E.  
 
3.4 RESULTS 
Liver-specific overexpression of GPAT1 -- To examine the effects of GPAT1 overexpression on 
hepatic lipid metabolism, chow-fed Wistar rats were studied 5-7 days after treatment with 1.0 - 2.0 x 
1012 particles/mL of Ad-GPAT1 or Ad-EGFP virus.  The recombinant adenovirus employed directs 
expression of a Flag-tagged version of GPAT, allowing specific detection of the overexpressed 
protein in virus-transduced tissues.  Rats treated with Ad-GPAT1 had 2.7-fold higher liver NEM-
resistant GPAT1 activity than rats treated with Ad-EGFP virus (Figure 3.2A).  No increase in NEM-
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 resistant GPAT1 activity was detected in epididymal fat from Ad-GPAT1-treated rats (Ad-EGFP 0.36 
± 0.1 and Ad-GPAT1 0.41 ± 0.1 nmol/min/mg protein; n = 6).  GPAT1-Flag expression was detected 
in liver but not in skeletal muscle or heart from Ad-GPAT1-treated rats and no GPAT1-Flag was 
detected in liver from Ad-EGFP-treated rats (Figure 3.2B).  EGFP expression was detected in liver 
by Western blot in all Ad-EGFP-treated rats (data not shown).  Plasma ALT levels were within the 
normal range in both Ad-GPAT1- and Ad-EGFP-treated rats, and ALT values did not differ between 
groups, indicating that the viral treatments did not cause significant cytotoxic effects (Table 3.1). 
 
Hepatic overexpression of GPAT1 causes hepatic steatosis, hypertriglyceridemia, and muscle TAG 
accumulation – Overexpression of GPAT1 increased hepatic TAG content 2.7-fold (Figure 3.3A).  
Thus, GPAT1 appeared to increase hepatic glycerolipid synthesis.  The hepatic steatosis observed in 
Ad-GPAT1-treated rats was accompanied by a 2.6-fold increase in total plasma TAG concentration 
(Table 3.1).  TAG content in plasma VLDL fractions was 4-fold higher in Ad-GPAT1-treated rats 
(Figure 3.3C).  Although total plasma cholesterol content did not change with Ad-GPAT1-treatment 
(Table 1), VLDL cholesterol was 2.5-fold higher in Ad-GPAT1-treated rats, whereas the LDL 
cholesterol concentration was slightly lower (Figure 3.3D).  These data suggested that GPAT1 directs 
the synthesis of a TAG pool that is available for both cytosolic storage and secretion in VLDL.  To 
determine whether the increase in plasma TAG in Ad-GPAT-1-treated rats was due to an increase in 
secretion of VLDL particles or to an increase in TAG incorporation into VLDL particles, VLDL 
ApoB100 and ApoB48 levels were determined by SDS-PAGE analysis of VLDL lipoprotein 
fractions.  No differences in ApoB100 or ApoB48 protein levels were observed (data not shown), 
suggesting that the increase in VLDL TAG was due to an increased amount of TAG incorporated into 
each particle rather than an increase in the number of VLDL particles secreted.  These results are 
similar to those observed in mice treated with Ad-GPAT1, which had increased TAG secretion with 
no increases in plasma ApoB concentration (34). In addition to increased TAG content in liver and 
plasma, gastrocnemius muscle in Ad-GPAT1-treated rats contained more TAG (Figure 3.3B), and 
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 soleus muscle (EGFP 94.6 ± 37.6; GPAT 185.7 ± 54.0 ng/ug protein, p = 0.25) and heart muscle  
(EGFP 14.5 ± 1.4; GPAT 21.2 ± 2.4 ng/ug protein, p = 0.07) also had a trend towards higher TAG 
content in Ad-GPAT1-treated rats.   Elevated plasma TAG and fatty acid concentrations may have 
contributed to this peripheral TAG accumulation (Table 3.1).  The high circulating plasma TAG 
concentration did not appear to affect adipose tissue, as body weight and fat pad weights of Ad-
GPAT1 and Ad-EGFP-treated rats did not differ (Table 3.1).  Additionally, there were no differences 
in food intake or plasma leptin concentrations between groups, suggesting that hepatic GPAT1 
overexpression did not alter satiety or adipokine production (Table 3.1).   
 
Ad-GPAT1-treated rats were insulin resistant –  
Since hepatic steatosis, hypertriglyceridemia, and peripheral TAG accumulation often 
accompany insulin resistance, we proposed that Ad-GPAT1-treated rats would be less insulin 
sensitive than Ad-EGFP-treated rats.  Although insulin to glucose ratios between the two groups did 
not differ, Ad-GPAT1-treated rats had a lower liver glycogen content after a 4 h fast, suggesting that 
Ad-GPAT1-treated rats might have hepatic insulin resistance (Table 3.1).  To measure insulin 
sensitivity, we performed hyperinsulinemic-euglycemic clamp studies.  Ad-GPAT1-treated rats 
maintained euglycemia with a 40% lower rate of glucose infusion during clamp experiments 
compared to Ad-EGFP-treated rats (Figure 3.4A), confirming whole-body insulin resistance. 
 
 Basal hepatic glucose output was slightly elevated in Ad-GPAT1-treated rats (Figure 3.4B).  
During the clamp procedure, insulin suppressed hepatic glucose output 77% in Ad-EGFP-treated rats, 
but only 37% in Ad-GPAT-treated rats, indicating that the livers of  Ad-GPAT1-treated rats were 
insulin resistant (Figure 3.4B).  Although the amount of glucose incorporated into liver glycogen was 
22% lower in Ad-GPAT1-treated rats, the difference was not significant (Figure 3.4C).  To confirm 
that the increase in glucose production was due to increased hepatic gluconeogenesis, we examined 
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 Table 3.1: Physiologic and plasma measurements. a  
 
  EGFP  GPAT 
Physiologic parameters after 4 h 
fast 
    
     
Body weight, g  342 ± 8  329 ± 6 
Food intake/day  26.5 ± 1.7  24.1 ± 1.2 
Liver weight, g  15.8 ± .05  16.5 ± 0.7 
Liver weight, % of BW  4.6 ± 0.1  5.0 ± 0.1 
Liver glycogen, µg/mg protein  23 ± 2  17 ± 3 ** 
Epididymal fat weight, g  3.6 ± 0.2  3.3 ± 0.1 
Epididymal fat wt, % of BW  1.0 ± 0.1  1.0 ± 0.1 
     
Plasma parameters after 4 h fast     
     
ALT, U/L  67 ± 19  47 ± 7 
TAG, mg/dL  179 ± 28  472 ± 97 ** 
Cholesterol, mg/dL  91 ± 7  103 ± 7 
Fatty acid, µM  120 ± 0.0  190 ± 30 * 
β-Hydroxybutyrate, mg/dL  2.0 ± 0.2  2.1 ± 0.1 
Blood glucose, mg/dLb  128 ± 4  118 ± 3 * 
Insulin, ng/mL  4.5 ± 0.4  3.4 ± 0.5 
Insulin/glucose ratio  0.035 ± 0.004  0.029 ± 0.004 
Leptin, ng/mL  3.4 ± 0.6  2.4 ± 0.5 
TNF-α, pg/mL  77 ± 14  50 ± 14 
IL-6, pg/mL  27 ± 11  38 ± 9 
IL-1β, pg/mL  15 ± 4  24 ± 4 
 
aRats were treated with 1.0-2.0x 1012 particles/mL of Ad-GPAT1 or Ad-EGFP virus for 5-7 days and 
fasted for 4 h before samples were collected.  Results are expressed as mean ± SE.  * p < 0.05  ** p < 
0.01  Triacylglycerol (TAG), , alanine aminotransferase (ALT), tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), interleukin-6 (IL-6).  4 h fast (Ad-EGFP, n = 9; Ad-GPAT, n = 11).   
 
b After an overnight fast, the glucose values were 127.4 ± 4.5 (Ad-EGFP; n=8) and 126.2  ±  4.7 (Ad-
GPAT1; n=8), and the insulin values were 0.76 ± 019 (Ad-EGFP; n=8)  and 0.93 ± 0.1 (Ad-GPAT; 
n=8). 
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Figure 3.2: GPAT1 activity and expression in rat liver.   
Rats were treated with 1.0-2.0 x 1012 particles/mL of Ad-GPAT1 or Ad-EGFP virus for 5-7 d. (Ad-
EGFP, n = 9; Ad-GPAT1, n =11).  A) GPAT1 enzyme activity was determined in liver total 
membranes after inhibiting endoplasmic reticulum GPAT with NEM.  Results are expressed as mean 
± SE.  B) Anti-FLAG western blot of total membranes from primary hepatocytes infected with Ad-
GPAT1 (Control), from liver of a rat infected with Ad-EGFP (EGFP), and from liver, gastrocnemius 
muscle (2 lanes), and heart (2 lanes) of rats infected with Ad-GPAT. 
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Figure 3.3:  Liver, skeletal muscle, and VLDL triacylglycerol (TAG) content was increased in 
Ad-GPAT1-treated rats.  Rats were treated with 1.0-2.0 x 1012 particles/mL of Ad-GPAT1 or Ad-
EGFP virus for 5-7 days and fasted for 4 h before tissue collection.  (Ad-EGFP, n = 9 and Ad-
GPAT1, n = 11 for liver and gastrocnemius). Results are expressed as mean ± SE.  A) Liver TAG.  B) 
Gastrocnemius muscle TAG.  Plasma lipoprotein fractions were separated by FPLC.  Triglyceride and 
cholesterol are reported as averages (EGFP, n = 4; GPAT, n = 6).  C) VLDL TAG (fraction 14; * 
p<0.05).  D) VLDL cholesterol (fraction 14; p< 0.06). 
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Figure 3.4A-C: Ad-GPAT1-treated rats were insulin resistant.  Rats were treated with 1.0-2.0 x 
1012 particles/mL of Ad-GPAT1 or Ad-EGFP virus for 7 d and food-deprived for 24 h before 
hyperinsulinemic-euglycemic clamp experiments  (Ad-EGFP, n = 8;  Ad-GPAT1, n = 8).  A) Glucose 
infusion rate. B) Basal and insulin-stimulated hepatic glucose output.  C)  Glucose incorporation into 
liver glycogen (p = 0.36).   
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Figure 3.4 D-F: Ad-GPAT1-treated rats were insulin resistant  D) PEPCK and E) G6Pase mRNA 
expression were measured in liver from Ad-GPAT1-treated rats fasted for 4 h or fasted for 24 h 
followed by hyperinsulinemic-euglycemic clamps for 3 h.  PEPCK mRNA expression after clamp (n 
= 6).  G6Pase mRNA expression after clamp (p = 0.33) (n = 6).  F) PEPCK protein expression after 
clamp (n = 8).   
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hepatic phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
expression after the clamp procedure.  Liver PEPCK mRNA and protein levels were 3-fold and 1.6- 
fold higher, respectively, in Ad-GPAT1-treated rats (Figure 3.4D-F).  Although hepatic G6Pase 
mRNA expression was 2.7-fold higher in Ad-GPAT1-treated rats after the clamp, the difference was 
not significant (Figure 3.4E).   
Basal glucose disposal rates were similar in Ad-GPAT1- and Ad-EGFP-treated rats (Figure 
3.5A). During the clamp, insulin elevated the glucose disposal rate 3-fold in Ad-EGFP-treated rats, 
but only 2-fold in Ad-GPAT1-treated rats, indicating that hepatic overexpression of GPAT1 reduced 
peripheral insulin sensitivity.   Hepatic overexpression of GPAT1 also lowered 2-deoxyglucose 
uptake into gastrocnemius muscle by 40%, suggesting reduced uptake of glucose by skeletal muscle 
(Figure 3.5A, B).  The 175% increase in gastrocnemius TAG content observed in Ad-GPAT1-treated 
rats may have contributed to the altered insulin sensitivity (Figure 3.3B).  In other muscles examined, 
the differences in 2-deoxy-glucose uptake did not reach significance, but uptake into Ad-GPAT 
soleus muscle was reduced 30 % (EGFP 809 ± 121; GPAT 563 ± 84, p = 0.12), and glucose 
incorporation into Ad-GPAT vastus lateralis muscle glycogen was reduced 58 % (EGFP 27.4 ± 8.1; 
GPAT 11.6 ± 1.7, p = 0.07).  These data, taken together, with the marked reduction in gastrocnemius 
uptake of glucose, suggest that hepatic overexpression of GPAT1 reduces glucose metabolism and 
insulin sensitivity in skeletal muscle.  
 
Elevated hepatic DAG contributes to hepatic insulin resistance through activation of PKCε –
Hepatic steatosis is often present in animals with insulin resistance, but the link between increased 
hepatic TAG accumulation and reduced hepatic insulin sensitivity is not completely understood.  It 
has been hypothesized that lipid metabolites accumulate in the liver in conjunction with increased 
TAG synthesis and act in signaling pathways to disrupt insulin responses.  For example, DAG and 
acyl-CoA accumulation accompany insulin resistance in muscle and liver  [118, 184-189].  GPAT1-/- 
mice  
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Figure 3.5: Skeletal muscle glucose metabolism was impaired in Ad-GPAT1-treated rats.   
Rats were food-deprived for 24 h before hyperinsulinemic-euglycemic clamp experiments.   A) Basal 
and insulin-stimulated hepatic glucose disposal rates.  B) 2-Deoxyglucose uptake in gastrocnemius 
muscle.  Ad-EGFP, n = 8; Ad-GPAT1, n = 8. 
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 fed a high-fat safflower-oil diet for 3 weeks were protected from diet-induced insulin resistance and 
had an increased hepatic content of acyl-CoA, decreased content of DAG, and less activation of 
protein kinase Cε  (PKCε) [14].  To determine whether overexpression of GPAT1 would lead to the 
opposite changes in hepatic lipid intermediates, we measured the content of LPA, DAG and acyl-CoA 
in livers from Ad-GPAT1- and Ad-EGFP-treated rats.  Total hepatic LPA content was elevated 4-fold 
in Ad-GPAT1-treated rats, 16:0-LPA was elevated 5-fold, and other hepatic LPA species (14:0-, 
18:1-, and 16:1- LPA species) were elevated to a lesser extent compared to Ad-EGFP-treated rats 
(Figure 3.6A).  Total hepatic acyl-CoA content, however, did not differ between Ad-GPAT1 and Ad-
EGFP-treated rats, although the hepatic content of 18:0-CoA was lower (Figure 3.6B).  Hepatic DAG 
content was elevated 2-fold in Ad-GPAT1-treated rats (Figure 3.6C).  The most prominent elevations 
were in DAG species that contained palmitate (16:0-18:1, 16:0-16:0, and 16:0-18:2), but several 
DAG species containing oleate and stearate were also elevated compared to Ad-EGFP-treated rats 
(Figure 3.6C).  Despite elevated amounts of DAG species containing 18:1, hepatic stearoyl-CoA 
desaturase-1 (SCD-1) expression was similar in Ad-GPAT1- and Ad-EGFP-treated rats (Table 3.2). 
 
In liver from insulin resistant rodents DAG accumulation has been associated with increased 
PKCε activity and defects in insulin stimulation of IRS-2 tyrosine phosphorylation [188].  Because 
high-fat fed GPAT1-/- mice had lower hepatic PKCε activity [14], we measured PKCε activity in liver 
from Ad-GPAT1 and Ad-EGFP-treated rats to determine whether elevated DAG could be causing 
insulin resistance in Ad-GPAT1-treated rats through this mechanism.  Membrane-associated activated 
PKCε was 30% higher in liver from Ad-GPAT1-treated rats (Figure 3.7), suggesting that PKCε 
activation could have contributed to the insulin resistance observed in Ad-GPAT1-treated rats.   
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Figure 3.6A-B: Hepatic lipid metabolites were altered in Ad-GPAT1-treated rats.  Rats were 
treated with 1.0-2.0 x 1012 particles/mL Ad-GPAT1 or Ad-EGFP for 5-7 days and food-deprived 4 h 
before tissues were collected.  Liver lipid metabolites were measured by mass spectrometry.  A) Total 
acyl-CoA content (inset) and acyl-CoA species (18:0-CoA *p<0.03).  B) Total LPA content (inset) 
(**p< 0.001) and LPA species (* p<0.01; **p<0.001).   
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Figure 3.6C: Hepatic lipid metabolites were altered in Ad-GPAT1-treated rats. Rats were treated 
with 1.0-2.0 x 1012 particles/mL Ad-GPAT1 or Ad-EGFP for 5-7 days and food-deprived 4 h before 
tissues were collected.  Liver lipid metabolites were measured by mass spectrometry.  C) Total DAG 
(inset) (**p<0.001) and DAG species (* p< 0.05) (** p<0.001).  Ad-EGFP n = 9; Ad-GPAT1 n = 11.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Hepatic PKCε activity was elevated in Ad-GPAT1-treated rats.  Rats were treated 
with 1.0-2.0 x 1012 particles/mL Ad-GPAT1 or Ad-EGFP for 5-7 days and fasted for 4 h before 
tissues were collected.  Liver cytosolic and membrane fractions were isolated, and the amount of 
PKCε in each fraction was determined by Western Blot.  Ad-EGFP, n = 4; Ad-GPAT1, n = 4.   
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Figure 3.8: NF-κB activity was lower in Ad-GPAT1-treated rats.  Rats were treated with 1.0-2.0 x 
1012 particles/mL Ad-GPAT1 or Ad-EGFP for 5-7 days.  Tissues were collected after a 4 h fast and 
NF-κB activity was measured in rat liver nuclear extracts with an ELISA kit.  Control (non-viral), n = 
4; After 4 h fast Ad-EGFP n = 19; Ad-GPAT1 n = 21. Results are presented as mean ± SE. 
 
 
 
 
Table 3.2: Hepatic gene expression. 
 
Gene expression after 4 h fast  EGFP  GPAT 
     
SCD-1  1.0 ± 0.2  0.8 ± 0.1 
TNF-α  1.0 ± 0.2  0.9 ± 0.2 
IL-1β  1.0 ± 0.2  1.0 ± 0.3 
 
Rats were treated with 1.0-2.0x 1012 particles/mL of Ad-GPAT1 or Ad-EGFP virus for 5-7 days and 
fasted for 4 h before livers were collected.  Results expressed as mean ± SE.  Stearoyl-CoA 
desaturase-1 (SCD-1), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) 
(EGFP, n = 5; GPAT n = 5). 
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 Hepatic inflammation did not contribute to insulin resistance in Ad-GPAT1-treated rats – 
Because recent studies of insulin resistance have focused on the role of the immune system in the 
development of hepatic insulin resistance, we measured plasma cytokine levels and hepatic NF-κB 
activity.  Plasma IL-1β, IL-6, and TNFα concentrations did not differ between Ad-GPAT1-treated  
and Ad-EGFP-treated rats (Table 3.1), and hepatic expression of TNF-α and IL-β did not differ 
between groups (Table 3.2).  Additionally, hepatic NF-κB activity was 50% lower in Ad-GPAT1-
treated rats compared to Ad-EGFP-treated rats and untreated controls, indicating that hepatic 
overexpression of GPAT1 caused insulin resistance in the absence of increased hepatic inflammation 
(Figure3.8) 
 
3.5  DISCUSSION 
The major finding of this study was that overexpressing GPAT1 in liver caused hepatic 
steatosis and hepatic insulin resistance in the absence of obesity or high-fat feeding.  Surprisingly, 
TAG also accumulated in gastrocnemius muscle, in concert with development of insulin resistance in 
that tissue, possibly secondary to the increase in circulating VLDL-TAG and FFA.  GPAT is the 
committed step in glycerolipid synthesis, and GPAT1, normally up regulated by SREBP-1c under 
conditions in which lipogenesis is enhanced, appears to control the amount of TAG synthesized, even 
when food intake or composition is not altered. 
 
Hyperinsulinemic-euglycemic clamp studies confirmed that insulin resistance had developed 
in Ad-GPAT1-treated rats within 5-7 d of adenovirus treatment.  In the Ad-GPAT1-treated rats, forty 
percent less glucose was required to maintain euglycemia than in the control rats, and hepatic glucose 
output was 2.7-fold higher during the clamp, consistent with severely reduced hepatic insulin 
sensitivity.  The increased gluconeogenesis in Ad-GPAT1-treated rats was associated with elevated 
PEPCK mRNA and protein expression.  Although hepatic glycogen content was significantly lower 
in Ad-GPAT1-treated rats after a 4 h fast, hepatic glycogen synthesis was not suppressed during the 
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 clamp. These results suggest that GPAT1 overexpression impaired insulin suppression of 
gluconeogenesis but had little effect on insulin-stimulated glycogen synthesis.  
 
In addition to causing profound insulin resistance in liver, GPAT1 overexpression in liver 
also resulted in a lower insulin-stimulated systemic glucose disposal rate and less uptake of glucose 
into gastrocnemius muscle.  These data are consistent with a decreased rate of muscle glucose 
metabolism and suggest that hepatic GPAT1 overexpression increased peripheral insulin resistance.  
Although the uptake of 2-deoxyglucose was not statistically different in two other muscles, it is 
possible that hepatic overexpression of GPAT1 for a longer period than 7 days might lead to more 
severe peripheral insulin resistance.  Peripheral insulin resistance was associated with increases in the 
TAG content of skeletal and heart muscle.  Since Ad-GPAT1 was not expressed in these tissues, it is 
likely that the increase in intramuscular TAG content resulted from the elevated plasma VLDL-TAG 
and fatty acid available for muscle uptake and storage.  Although the uptake of 2-deoxyglucose was 
not statistically different in two other muscles, it is possible that hepatic overexpression of GPAT1 for 
a longer period than 7 days might lead to more severe peripheral insulin resistance.  Elevated plasma 
lipids can lead to TAG accumulation and insulin resistance in skeletal muscle [8, 193-195].  Ad-
GPAT1-treated rats ate the same amount of food, gained the same amount of weight as Ad-EGFP-
treated controls, and did not show differences in epididymal fat pad mass or plasma leptin 
concentrations.  Thus, alterations in body fat mass did not contribute to the systemic insulin resistance 
observed in Ad-GPAT1-treated rats.   
 
What caused hepatic insulin resistance when GPAT1 was overexpressed?  The frequent 
association of insulin resistance with TAG accumulation in liver and other tissues suggests that TAG 
or a related lipid metabolite antagonizes pathways of insulin signaling.  Consistent with this idea, 
experimental lowering of liver TAG content in other rodent models results in amelioration of hepatic 
and peripheral insulin resistance [14, 103].   Hepatic overexpression of GPAT1 increased liver TAG 
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 content 2.7-fold, and dramatically increased the intracellular content of immediate and downstream 
products of GPAT1, LPA and DAG.  In primary rat hepatocytes treated with Ad-GPAT1 and in livers 
from mice treated with Ad-GPAT1, we and others reported an increase in fatty acid incorporation into 
DAG and an increase in DAG content [15, 36, 37].  In the present study, the enrichment of 16:0 
species in both LPA and DAG reflects the preferred 16:0-CoA substrate of GPAT1 [29] and strongly 
suggests that both metabolites were derived from de novo synthesis rather than from the hydrolysis of 
membrane phospholipids.   
 
LPA is well-recognized as a ligand for G-protein coupled LPA receptors that stimulate cell 
growth [196], and extracellular LPA, acting via LPA receptors on adipocytes, inactivates glycogen 
synthase kinase 3 (GSK3) in a PI3K independent manner [197].  Thus, extracellular LPA signaling 
could enhance glycogen synthesis independent of insulin signaling, but we observed a decrease rather 
than an increase in hepatic glycogen content in Ad-GPAT treated animals in the current study.   
Moreover, there are no known inhibitory effects of extracellular or intracellular LPA on insulin 
signaling pathways.  DAG accumulation, however, and its concomitant activation of PKC isoforms 
has been implicated in the development of insulin resistance in skeletal muscle and liver [117, 198], 
and the activation of PKCε and PKCδ has been implicated in hepatic insulin resistance [188, 199, 
200].  Further, mice deficient in GPAT1, have a lower hepatic DAG content than wild type controls 
and are protected via a PKCε-mediated mechanism from high-fat-diet-induced insulin resistance [14].  
In the current study, PKCε activity was 30% higher in the livers of Ad-GPAT1-treated rats compared 
to control livers.  PKCε interacts with the insulin receptor and prevents tyrosine phosphorylation of 
IRS-2, thereby blocking insulin signaling upstream of IRS-2 [200].  High-fat feeding of wild type 
mice disrupts insulin stimulation of IRS-2-associated PI3K activity, but this pathway was maintained 
in GPAT1-/- mice, as was insulin-stimulated suppression of hepatic gluconeogenesis [14].  Thus, the 
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 failure of insulin to suppress hepatic PEPCK gene expression and gluconeogenesis in Ad-GPAT1-
treated rats may be due to PKCε-mediated inhibition of IRS-2-associated PI3K activity. 
 
SCD1 catalyzes the desaturation of 18:0 to 18:1, and reduced expression of SCD1, which was 
observed in GPAT1-/- mice [13, 15], is associated with decreased hepatic TAG synthesis [201, 202].  
In diet-induced obesity, SCD1 expression may be required for the development of hepatic insulin 
resistance [203].  Although low compared to 16:0 species, 18:1-species of LPA and DAG were 40% 
higher in Ad-GPAT1-treated rats, similar to a report of Ad-GPAT overexpression in mice in which 
SCD1 mRNA expression increased 10-fold [15].  In our study, however, no difference was observed 
in SCD-1 mRNA expression in Ad-GPAT1 and Ad-EGFP rats, indicating that SCD1 had not 
influenced insulin resistance.   
 
Although overexpression of GPAT1 in primary hepatocytes did not increase the amount of 
[14C]fatty acid that was incorporated into media TAG (19, 20), the amount of TAG in plasma did 
increase when GPAT1 was overexpressed in mice or rats.  In mice treated with Ad-GPAT1, the rate 
of TAG secretion increased 86% [15], and, similarly, we found that in Ad-GPAT1-treated rats plasma 
TAG was 2.6-fold higher than in controls, and that there was a large increase of TAG in the VLDL 
fraction.  These data suggest that the pool of TAG synthesized by GPAT1 is available both for 
storage and for incorporation into VLDL.  Because the amount of apoB in Ad-GPAT-treated mouse 
plasma [15] or in VLDL from Ad-GPAT-treated rats did not differ from controls, it is likely that 
GPAT1 overexpression increased the amount of TAG incorporated into VLDL but not the number of 
VLDL particles secreted.  Although total plasma cholesterol content was not elevated in Ad-GPAT1-
treated rats, plasma cholesterol was redistributed away from HDL and into the VLDL fraction.     
 
Several recent studies have implicated hepatic NF-κB activity, hepatocellular inflammatory 
pathways, and elevated hepatic expression of IL-1β, TNF-α, and IL-6 in the development of hepatic 
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 insulin resistance [204, 205].  However, compared to Ad-EGFP-treated rats, hepatic NF-κB activity 
was not elevated in Ad-GPAT1-treated rats, and neither hepatic expression of IL-1β and TNF-α nor 
plasma cytokine concentrations differed.  These data show that, at least over the short time frame of 
the current study (7 days), the fatty liver induced by GPAT1 overexpression did not cause hepatic 
inflammation and inflammatory cytokines did not contribute to insulin resistance in this model.   
 
The accumulation of glycerolipid metabolites has been implicated in the pathogenesis of 
hepatic insulin resistance, but a causal relationship has not been clearly established.  Interpretation of 
most animal models of hepatic steatosis and insulin resistance is complicated by underlying obesity, 
genetically-induced over-feeding, lipodystrophy, or alterations in adipokine production.  In our study, 
GPAT1 overexpression enhanced de novo glycerolipid synthesis in rat liver and caused hepatic 
steatosis, hypertriglyceridemia, and both hepatic and peripheral insulin resistance in the absence of 
obesity, high-fat feeding, or elevated inflammatory markers.  These data support the idea that liver 
lipid metabolism itself can play a central role in the development of both hepatic and systemic insulin 
resistance. Hepatic insulin resistance was associated with an elevated hepatic content of LPA, DAG, 
and TAG, as well as increased PKCε activation, whereas peripheral insulin resistance was associated 
with excess TAG storage in muscle.  Further study of the regulation of hepatic de novo glycerolipid 
synthesis and of the role of glycerolipid intermediates as intracellular signaling molecules promises a 
better understanding of the mechanisms involved in lipid-mediated hepatic insulin resistance.  
Enzymes in the pathway of glycerolipid biosynthesis may prove to be therapeutic targets for hepatic 
insulin resistance and type 2 diabetes.   
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CHAPTER IV.  IDENTIFICATION OF A NOVEL GPAT, GPAT4 
 
 
 Acyl-glycerol-3-phosphate acyltransferase-6 (AGPAT6) is a newly cloned enzyme 
with conserved acyltransferase motifs shared by known GPAT and AGPAT isoforms. 
AGPAT6 knock-out mice have reduced liver and adipose tissue TAG content, a phenotype 
consistant with a deficiency in either GPAT or AGPAT activity.  However, the specific 
acyltransferase activity of AGPAT6 had not been determined.  This chapter describes our 
work to identify AGPAT6 as a novel NEM-sensitive GPAT, GPAT4.  
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4.1  ABSTRACT:   
Elucidation of the metabolic pathways of triacylglycerol synthesis is critical to the 
understanding of chronic metabolic disorders such as obesity, cardiovascular disease, and 
diabetes.  Glycerol-sn-3-phosphate acyltransferase (GPAT) and sn-1-acylglycerol-3-
phosphate acyltransferase (AGPAT) catalyze the first and second steps in de novo 
triacylglycerol synthesis.  AGPAT6 is one of eight AGPAT isoforms identified through 
sequence homology, but the enzyme activity for AGPAT6 has not been confirmed.  Agpat6 
deficient mice have a subdermal lipodystrophy, reduced liver and adipose tissue 
triacylglycerol content, and resistance to high fat diet-induced obesity.  We found that in liver 
and brown adipose tissue from Agpat6-/- mice NEM-sensitive GPAT specific activity was 
60% lower than in tissues from wild type mice, but that AGPAT specific activity was similar 
in wild type and Agpat6-/- mice.  Over-expression of Agpat6 in Cos-7 cells increased an 
NEM-sensitive GPAT specific activity that used saturated and unsaturated 16 and 18 carbon 
acyl-CoA substrates similarly, and increased GPAT’s lysophosphatidic acid product.  
AGPAT specific activity was not increased in the AGPAT6-expressing cells.  Thus, “Agpat6-
/- mice” are actually deficient in a novel NEM-sensitive GPAT, GPAT4, and should be called 
Gpat4-/- mice. 
 
4.2  INTRODUCTION: 
The regulation of triacylglycerol (TAG) synthesis and metabolism plays an important 
role in whole body energy homeostasis in mammals, and dysregulation of TAG synthesis and 
oxidation pathways have been implicated in the pathogenesis of obesity, lipodystrophy, 
cardiovascular disease, insulin resistance, and type 2 diabetes.  De novo triacylglycerol 
synthesis begins with the formation of lysophosphatidic acid (LPA) through the acylation of 
glycerol-3-phosphate at the sn-1 position by sn-1 glycerol-3-phosphate acyltransferase 
(GPAT) (Figure 4.1). The second enzyme in de novo triacylglycerol synthesis, 1-
acylglycerol-3-phosphate acyltransferase (AGPAT), acylates lysophosphatidic acid (LPA) to 
form phosphatidic acid (PA).  Lipin (phosphatidic acid phosphohydrolase) converts PA to 
diacylglycerol (DAG), and diacylglycerol acyltransferase acylates DAG to form TAG.  PA 
and DAG are also precursors for glycerophospholipids.   
  
Three mammalian GPAT isoforms have been cloned [33, 34, 41].  GPAT1 and 
GPAT2 are located in the outer mitochondrial membrane, whereas GPAT3 is located in the 
endoplasmic reticulum.  GPAT1 is resistant to inactivation by sulfhydryl agents like N-
ethylmaleimide (NEM), prefers palmitoyl-CoA as a substrate compared to oleoyl-CoA, and 
plays a regulatory role in liver TAG synthesis [29].  GPAT2 is NEM-sensitive and has no 
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Figure 4.1.  Pathway of de novo glycerolipid synthesis.  GPAT isoforms located in mitochondria 
(GPAT1 and  2) and endoplasmic reticulum (GPAT3 and 4) catalyze the initial step in the synthesis 
of glycerophospholipids and triacylglycerol (TAG).  AGPAT isoforms catalyze the second step in this 
pathway by acylating lysophosphatidic acid to form phosphatidic acid (PA). Acyl-CoA used for -
oxidation or TAG synthesis is regulated reciprocally by carnitine palmitoyl transferase-1 (CPT-1) and 
GPAT1 [13].  Cardiolipin (CL), diacylglycerol (DAG), triacylglycerol (TAG), 
phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylcholine (PC), 
phosphatidylserine (PS), and fatty acid (FA). 
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  preference for palmitoyl-CoA [3].  Recently, the gene product previously called AGPAT8 in 
the NCBI database was shown to have NEM-sensitive GPAT activity and to lack AGPAT 
activity; this gene product was re-named GPAT3 [34].  Because siRNA knockdown of Gpat3 
in 3T3-L1 adipocytes reduces total GPAT activity by ~60% [4, 34], it is likely that GPAT3 is 
important for TAG synthesis in WAT.  However, GPAT3 is unlikely to play a major role in 
TAG synthesis in liver where its mRNA expression is very low [4, 34].  In liver, GPAT1 
accounts for 30-50% of the total GPAT activity [29].  The remaining hepatic GPAT activity 
is NEM-sensitive and microsomal, suggesting that one or more additional microsomal NEM-
sensitive GPAT isoforms must exist. 
 
Eight genes with predicted amino acid sequence similarities to GPAT1 have been 
named AGPAT isoforms 1-8.  AGPAT1 and 2 are well characterized and have high AGPAT 
activity [60, 61].  Mutations in AGPAT2 cause generalized human congenital lipodystrophy, 
with absent abdominal and subcutaneous adipose tissue, systemic insulin resistance, and 
hypertriglyceridemia [67].    Compared to AGPAT1 and 2, the AGPAT activities reported for 
AGPAT3-5 are extremely low [206]; no enzyme activity has been reported for AGPAT6 or 
7.   
 
We previously characterized mice with a targeted deletion in Agpat6 (Agpat6-/- mice; 
NP_848934) [4, 35].  These mice have a subdermal lipodystrophy, resistance to high-fat diet 
induced obesity, and a 50% reduction of TAG content in liver, adipose tissue and mammary 
epithelium, suggesting an important role for AGPAT6 in TAG synthesis in these tissues.  
AGPAT6 shares amino acid sequence homology with other glycerolipid acyltransferases at 
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Table 4.I: Acyltransferase motifs in E. coli and mouse AGPAT and GPAT isoforms  
 Motif Ia Motif IIa Motif IIIa Motif IVa Motif Vf
Functiona Catalysis  G-3-P binding G-3-P binding Catalysis  
AGPAT1 
(NP_061350) 
104 HQSSLD 140 GIIFIDR 173 FPEGTRNH 200 VPIIPIVNSSY 231 VLPPVSTEGLTPDD 
AGPAT2 
(NP_080488) 
98  HQSLID 137 GVYFINR 170 YPEGTRND 197 VPIIPVVYSSF 227 VLDAVPTNGLTDAD 
AGPAT6 (GPAT4e) 
(NP_061213) 
248 HTSPID 286 PHVWFER 320 FPEGTCIN 343 ATVYPVAIKYD 385 VWYLPPMTREKDED 
AGPAT8 (GPAT3d) 
(NP_766303) 
229 HRTRVD 268 VHIFIHR 301 FPEGTCLT 324 GTIYPVAIKYN 366 VWYMPPMTREEGED 
E. coli GPAT 
(plsB) (BAE78043) 306 HRSHMD 349 GAFFIRR 383 FVEGGRSR 417 ITLIPIYIGYE 
 
GPAT1b  
(NP_032175) 
230 HRSHID 272 GGFFIRR 313 FLEGTRSR 347 ILVIPVGISYD  
GPAT2c 
(NP_001074558) 
202 HKSLLD   
231 TCSPALR   
    or 
235 ALRALLR  
    or 
247 LGGFLPP[33] 
291 GSPGRLSA  
    or 
285 FLEEPPGS[33]  
320 ATLVPVAIAYD 
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aAcyltransferase motifs as we described in [30].  Bolded residues are highly conserved across these GPAT family members.  
Underlined amino acids are important for GPAT1 activity as determined by mutagenesis [29, 30]. Cysteines that may be targets for N-
ethylmaleimide are highlighted and italicized.  bPreviously called mtGPAT or mtGAT. cAlso identified as xGPAT1 [33].  dIdentified 
in GenBank as AGPAT8, but has only GPAT activity [34].  eIdentified in GenBank as AGPAT6, but has only GPAT activity as 
reported here. fMotif V as described in [35]. 
 
 
 
 
 
 
 
 
 conserved motifs I-V (Table 4.1), and is closely related to GPAT1 and 2 in motifs I-IV, 
which were identified as important for acyltransferase catalysis and glycerol-3-phosphate 
binding domains [30].  AGPAT6 shares 66% amino acid homology with “AGPAT8”, 
recently identified as GPAT3 [34], and confocal microscopy shows that AGPAT6 localizes 
to the endoplasmic reticulum [35]. 
 
In previous studies of AGPAT6, we were unable to detect AGPAT or GPAT activity 
in insect or Cos-7 cells transfected with Agpat6 constructs [35].  Convinced, however, that 
AGPAT6 must have either AGPAT or GPAT activity, we re-cloned Agpat6 with a C-
terminal Flag epitope tag into pcDNA3.1, transfected Cos-7 cells, and measured AGPAT and 
GPAT activities.  We also measured these enzyme activities in liver and adipose tissue from 
Agpat6-/- mice.  Our studies now identify Agpat6 as a gene encoding the primary microsomal 
NEM-sensitive GPAT activity in liver, GPAT4. 
 
4.3  METHODS: 
 
Agpat6-/- mice.   
Agpat6 -/- mice were generated from a gene-trap cell line identified in BayGenomics, 
a gene-trapping resource [4, 35].  This strain was backcrossed to C57BL/6J for at least four 
generations.  The mice were housed in a barrier facility with a 12 h light/12 h dark cycle, and 
fed a chow diet containing 4.5% fat (Ralston Purina, St. Louis, MO).  All animal protocols 
were approved by the institutional animal care and use committee.  Tissues were harvested 
from 6 month old mice, snap-frozen in liquid nitrogen, and stored at -80°C.  A previous 
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 characterization of the Agpat6-/- mice revealed a similar phenotype in adipose tissue and liver 
of males and females [4, 35], and both sexes were used in the studies described here.   
 
Cloning of Agpat6.   
Agpat6 was amplified by PCR from mouse liver RNA at 57.5 ˚C with Pfx50 (Invitrogen) 
using a forward primer (5’caccggatccacgtgcgtcctccaccat) containing a BamHI restriction site 
(bold) and a reverse primer (5’ccctctagactacttgtcgtcatcgtccttgtagtcggaccggctgcggtcct) 
containing a Flag epitope sequence (underlined) and an XbaI restriction site (bold). The 
amplification product was digested with BamHI and XbaI and ligated into the similarly 
digested pcDNA3.1 mammalian expression vector (Invitrogen).   
 
Nucleofection of Cos-7 cells with Agpat6.   
Cos-7 cells were grown in DMEM high glucose (GIBCO) with 10% FBS and 1% 
penicillin/streptomycin.  The cells were grown to confluence and passaged one day before 
nucleofection.  Cells were harvested and 4.0 x 106 cells were nucleofected with 12 µg Agpat6 
or empty vector pcDNA3.1 plasmid DNA in 100 µL of NucleofectorTM Kit V Solution using 
the NucleofectorTM system (AMAXA Biosystems).  Cells were then transferred to 100 mm 
cell culture dishes containing RPMI and 10 % FBS and 1% penicillin/streptomycin, and were 
harvested 18 h later. 
 
Membrane isolation and measurement of GPAT activity.   
Liver or adipose tissue was homogenized in Medium I + DTT (250 mM sucrose, 10 
mM Tris, pH 7.4, 1 mM EDTA, and 1 mM DTT) with 10 up-and-down strokes in a Teflon-
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 glass motor-driven homogenizer.  Homogenates were centrifuged at 100,000 x g for 1 h to 
obtain total membrane fractions.  The membrane pellet was re-homogenized in Medium I  + 
DTT and stored in 100 µL aliquots at -80º C.  GPAT specific activity was assayed at 23 oC 
for 10 min in a 200 µL reaction mixture containing 75 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 
2 mg/mL bovine serum albumin (essentially FA-free), 1 mM DTT, 8 mM NaF, 300 µM 
[3H]glycerol-3-phosphate, and 80 µM palmitoyl-CoA [183].  The reaction was initiated by 
adding 2.5-7.5 µg (WAT), 5-15 µg (BAT), or 10-30 µg (liver) total membrane protein to the 
assay mixture after incubating the membrane protein on ice for 15 min in the presence or 
absence of 1 mM NEM.  These assays measured initial rates.  The reaction was stopped by 
adding 1% perchloric acid and the products were extracted into chloroform [191].  NEM-
sensitive activity is calculated as the total GPAT activity minus the GPAT activity that is not 
inhibited by NEM.  For nucleofected Cos-7 cells, culture dishes were scraped with Medium I 
+ DTT and the samples were homogenized and centrifuged as described above to obtain total 
membrane fractions.  GPAT specific activity was measured as above with 5-15 µg of total 
Cos-7 membrane protein.  To identify the products from the GPAT assay, the chloroform 
extracts were spotted on a silica H thin layer chromatography plate (Analtech) together with 
authentic standards (Avanti) and developed in CHCl3/pyridine/formic acid (88%) (50/30/7; 
v/v).  The plates were exposed to iodine vapor, and the bands corresponding to LPA, PA, and 
DAG were scraped into scintillation vials containing Cytoscint (ICN) and counted.  To 
determine acyl-CoA preference, 60 µM of each of several acyl-CoA species and 10-20 µg 
protein were used in the GPAT assay. 
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 AGPAT assay.   
AGPAT specific activity was assayed at 37˚ C in a 100 µl mixture containing 100 
mM HEPES-NaOH pH 7.5, 200 mM NaCl, 10 mM EDTA, 8 mM NaF, 1 mg/ml bovine 
serum albumin (fatty acid free), 1 mM DTT, 5% (w/v) glycerol, 40 µM oleoyl-CoA, and 20 
µM 1-[3H]oleoyl-LPA (1 µCi, Perkin-Elmer NET-1100).  The reaction was initiated by 
adding 5 µg of total membrane protein to the assay mixture.  Fifteen µl of the reaction 
mixture was removed at indicated time points up to 10 min and spotted directly onto a Silica 
H plate together with authentic standards.  The radio labeled PA product was separated from 
the radio labeled LPA substrate in chloroform:pyridine:formic acid (50/30/7; v/v).  Authentic 
lipid standards for LPA and PA were visualized by exposure to iodine vapor.  Spots 
corresponding to PA were scraped into 500 µl methanol:water (1:1), Cytocint (ICN) was 
added and radioactivity was quantified. 
 
Immunoblotting.   
Cos-7 cell total membrane proteins were separated on an 8% poly-acrylamide gel 
containing 1% SDS, transferred to a PVDF membrane (Bio-Rad), and incubated with mono-
clonal antibody against the FLAG epitope (Clone M2, Sigma).  For chemiluminescent 
detection, the immunoreactive bands were visualized by incubating the membrane with 
horseradish peroxidase-conjugated goat anti-mouse IgG and PicoWest reagents (Pierce) 
according to the manufacturer’s instructions.  
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 Gene expression analyses.   
Total RNA was extracted from mouse tissues with TRIzol (Invitrogen).  Two µg of 
RNA were reverse-transcribed with oligo dT and random primers (Invitrogen).  Five percent 
of the resulting cDNA was used for each real-time RT-PCR reaction.  Real-time RT-PCR 
was performed in duplicate with Quantitect SYBR Green PCR mix (QIAGEN) in an iCycler 
Realtime Detection System (BioRad) [4, 207].  Data presented were derived from starting 
quantity (SQ) values normalized by the square root of the product of values obtained for the 
housekeeping genes beta-2-microglobulin (β2m) and TATA box binding protein (Tbp), or to 
18S rRNA.  Primer sequences used in this study have been described previously [207] or are 
shown in Table 4.2.  Primers for Gpat3 were previously cited as Agpat8 [4]. 
 
Table 4.2.  Primer sequences used in real-time PCR experiments 
Gene  Forward    Reverse 
β2m  5’cagcatggctcgctcggtgac  5’cgtagcagttcagtatgttcg 
Gpat1  5’agcaagtcctgcgctatcat  5’ctcgtgtgggtgattgtgac 
Gpat2  5’aagaaagaggtacagcgtatcc  5’gtggagagccctcctgcacag 
Gpat3  5’gtacatgcctcccatgactag  5’gatccgttgcccacgatcatc 
18S rRNA 5’accgcagctaggaataatgga  5’gcctcagttccgaaaacca 
 
Statistics.  Data are shown as mean ± S.E. Significance was established using Student’s t 
test.   Differences were considered significant at p< 0.05. 
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 4.4  RESULTS: 
Agpat6-/- mouse tissues have lower NEM-sensitive GPAT activity   
To determine whether tissues from Agpat6-/- mice have lower GPAT activity, we 
measured GPAT activity in total membrane fractions from liver, BAT, and gonadal WAT in 
the presence and absence of NEM.  Total GPAT activity was 49% lower in liver from 
Agpat6-/- mice (p < 0.001) (Figure 4.2A).  NEM-resistant activity (GPAT1) was similar in 
liver from knockout and wild-type mice (Figure 4.2B), but the NEM-sensitive activity was 
reduced 65% (p < 0.0001) (Figure 4.2C).  AGPAT activity was unchanged in Agpat6-/- 
mouse liver (Figure 4.2D).  In Agpat6-/- BAT, total GPAT specific activity was reduced 50% 
(p < 0.01) and NEM-sensitive specific activity was reduced 65% (p < 0.001) (Figure 4.3).  
However, GPAT specific activities were identical in gonadal WAT from wild type and 
Agpat6-/- mice (Figure 4.3).  Thus, liver and BAT tissue from Agpat6-/- mice exhibit normal 
AGPAT activity, but reduced NEM-sensitive microsomal GPAT activity. 
 
Expression of Gpat1-3 mRNA transcripts in Agpat6-/- mice 
BAT from Agpat6-/- mice does not show altered expression of mRNA for Agpat1-5, 7 
or 8 [4].  To determine whether the deficiency of microsomal GPAT activity altered the 
mRNA expression of other GPAT isoforms, we measured the mRNA expression of Gpat1, 2, 
and 3 in liver, BAT, and inguinal WAT from Agpat6-/- mice.  Gpat1 expression was 2-fold 
higher in liver of Agpat6-/- mice (Table 4.3), but this increase in mRNA expression did not 
correspond to an increase in GPAT1 (NEM-resistant) activity (Figure 4.2C).  Agpat6-/- and 
wild-type mice had similar expression levels for Gpat2 and Gpat3 in liver and for Gpat1, 
Gpat2, and Gpat3 in BAT and WAT. 
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Figure  4.2.  NEM-sensitive GPAT specific activity was reduced in liver from Agpat6-/- mice.   In 
female mice GPAT specific activity was measured in liver total particulate preparations from female 
mice as described in Methods, (A), total activity; (B), NEM-sensitive activity, and (C), NEM-resistant 
activity.  AGPAT specific activity (D) in total particulate preparations was measured as described in 
Methods. (n =6) 
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Table 4.3.  mRNA levels of GPAT enzymes in wild-type and Agpat6–/– mouse tissues.  
*, p < 0.05 vs. wild-type  (n=4). 
 
 
Liver Brown adipose tissue 
Inguinal white adipose 
tissue 
 Wild-type Agpat6–/– Wild-type Agpat6–/– Wild-type Agpat6–/– 
Gpat1 0.20 ± 0.02 0.37 ± 0.1 * 0.73 ± 0.16 0.84 ± 0.23 0.07 ± 0.03 0.06 ± 0.05 
Gpat2 0.10 ± 0.04 0.08 ± 0.02 0.05 ± 0.002 0.03 ± 0.03 0.08 ± 0.08 0.11 ± 0.17 
Gpat3 0.64 ± 0.13 0.80 ± 0.19 1.41 ± 0.64 1.00 ± 0.19 2.05 ± 0.62 1.58 ± 1.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEM Resistant
WT KO
NEM Sensitive
WT KO
Activity:
0
0.4
0.8
1.2
WT KO
G
PA
T 
S.
A
.  
  
nm
ol
/m
in
/m
g 
pr
ot
ei
n
WT KOWT KO
0
2
4
6
8
10
WT KO
1.6
Brown Adipose Tissue
Total
White Adipose Tissue
NEM ResistantNEM SensitiveActivity: Total
G
PA
T 
S.
A
.  
  
nm
ol
/m
in
/m
g 
pr
ot
ei
n
p=0.002
p=0.001G
PA
T 
S.
A
.  
  
nm
ol
/m
in
/m
g 
pr
ot
ei
n
G
PA
T 
S.
A
.  
  
nm
ol
/m
in
/m
g 
pr
ot
ei
n
 
Figure 4.3.  NEM-sensitive GPAT specific activity is reduced in brown adipose tissue 
(BAT) but not in gonadal adipose tissue (WAT).  Total, NEM- sensitive, and NEM-
resistant GPAT specific activity was measured in BAT from male mice and in gonadal WAT 
from female mice., WT=wild type  and  KO=Agpat6-/-  mice. (n = 6)  
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Overexpression of Agpat6/Gpat4 in Cos-7 cells increases NEM-sensitive GPAT activity 
To further investigate the enzyme activity encoded by Agpat6/Gpat4 in a 
heterologous cell system, we expressed Gpat4 cDNA tagged with a FLAG epitope in Cos-7 
cells.  Protein expression levels were monitored by Western blot using an anti-FLAG 
antibody (Figure 4.4A).  Cells transfected with the Gpat4 expression construct exhibited 
60% higher NEM-sensitive GPAT activity than cells transfected with vector (p < 0.01), 
whereas AGPAT activity was similar between the two (Figure 4.4 B, C).  The products of 
the GPAT assay were analyzed by thin layer chromatography and showed a 2-fold increase 
in labeled LPA and a 70% increase in labeled PA in samples from Gpat4-transfected cells 
(Figure 4.4D).  The relative distribution of LPA, PA, and DAG products of GPAT assays 
was similar in cells transfected with empty vector or Gpat4; there was no relative increase in 
PA, which might be expected with AGPAT activity (Figure 4.4E).  Thus, overexpression of 
Gpat4 increased both NEM-sensitive GPAT activity and flux through the de novo 
glycerolipid synthetic pathway. 
 
 To determine whether GPAT4 has a preference for a specific acyl-CoA substrate, we 
measured GPAT activity in Cos-7 cell total membranes from Agpat6-transfected cells in the 
presence of acyl-CoA substrates of varying chain length and saturation.  Although able to use 
C12:0-CoA, GPAT4 preferred to use acyl-CoA substrates with 16 or 18 carbons as compared 
to C12:0- or C20:4-CoA (Figure 4.4F).    
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Figure 4.4.  Overexpression of GPAT4 in Cos-7 cells increases NEM-sensitive GPAT 
activity.  Cos-7 cells were transfected with pcDNA3.1 or with Gpat4.  A) Immunoblot of 
Cos-7 cell total membrane fractions against the Flag epitope (2 independent transfections);  
B) NEM-sensitive GPAT activity in Cos-7 total membrane fraction (n = 6,  p<0.01); C) 
AGPAT specific activity in Cos-7 cell total membrane fraction (n =4); D) Radio labeled 
glycerolipid products from GPAT assays of Cos-7 cell total membranes were separated by 
TLC and quantified as described in Methods;  E) Distribution of radio labeled glycerolipid 
products from GPAT assay as a percentage of total counts (average of 2 independent 
experiments);  F) Total GPAT activity in Cos-7 total membrane preparations with different 
acyl-CoA substrates (60 µM) (average of 2 independent experiments). 
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 4.5  DISCUSSION: 
Agpat6-/- mice have a subdermal lipodystrophy and reduced TAG content in BAT, 
WAT, liver, and mammary epithelium, suggesting that AGPAT6 plays an important role in 
TAG synthesis in these tissues [4, 35].  Because AGPAT catalyzes the second step in de novo 
TAG synthesis, the phenotype of the Agpat6-/- mice was consistent with the idea that 
AGPAT6 catalyzes that second step.  Based on amino acid sequence homology, mouse 
AGPAT6 appeared to be an AGPAT, but as shown here, acts as a GPAT instead.  When 
expressed in Cos-7 cells, we observed a 60% increase in NEM-sensitive GPAT activity, but 
no increase in AGPAT activity.  It is unclear why previous expression constructs for this 
enzyme, which contained C-terminal V5 or V5-His epitope tags, failed to exhibit GPAT or 
AGPAT activity when expressed in insect or Cos-7 cells [35]; it may be that these epitope 
tags interfered with enzyme action, while the Flag epitope used here did not.  Consistent with 
the true identity of AGPAT6 as a GPAT enzyme, the previously characterized Agpat6-
deficient mice have 65% lower NEM-sensitive GPAT specific activity in liver and BAT, but 
no change in AGPAT specific activity.  Thus, Agpat6 has been misidentified and actually 
encodes an NEM-sensitive GPAT activity.  As the fourth described GPAT, we have renamed 
it GPAT4.  Further, since the Agpat6-/- mice are deficient in GPAT and not in AGPAT 
activity, they should be called Gpat4-/- mice.   
 
Gpat4 mRNA is highly expressed in liver [35] and accounts for almost 50% of the 
total GPAT activity in wild-type mouse liver, as demonstrated by the 49% reduction in 
Gpat4-/- mice.  This loss in hepatic GPAT activity may be responsible for the 40-50% 
decrease in liver TAG reported for Gpat4-/- mice [4].  GPAT4 represented 65% of liver 
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 NEM-sensitive activity GPAT specific activity, suggesting that GPAT4 is the major NEM-
sensitive isoform in liver, but that one or more additional NEM-sensitive GPAT isoforms is 
also present.  To determine whether the mRNA expression of other GPAT isoforms increased 
in Gpat4-/-  mouse liver to compensate for the loss of GPAT4, we measured the expression of 
Gpat1, 2, and 3.  Neither Gpat2 nor Gpat3 mRNA expression was elevated in liver from the 
Gpat4-/-  mice, but Gpat1 mRNA was elevated 2-fold, although this increase did not 
correspond to an increase in NEM-resistant (GPAT1) GPAT specific activity.  Gene 
expression does not invariably correspond to protein expression, and GPAT1 enzyme activity 
may be regulated by posttranslational mechanisms [32].  We previously reported that the 
mRNAs for Agpat1-5, 7, and 8 did not change in BAT from the Gpat4-/-  mice [4]. 
 
GPAT4 also appears to be the primary NEM-sensitive GPAT in BAT, as 65% of the 
NEM-sensitive GPAT activity was lost in BAT from male Gpat4-/- mice.   NEM-resistant 
activity in Gpat4-/- BAT was unaltered, and none of the known GPAT isoforms was up 
regulated at the transcriptional level to compensate for the loss of GPAT4.  Interestingly, 
total and NEM-sensitive GPAT activities were not reduced in gonadal WAT from Gpat4-/- 
mice, despite the previous demonstration that the TAG content of WAT was reduced in 
chow-fed male Gpat4-/- mice [4].  It may be that additional, unknown GPAT isoforms are 
responsible for activity in white adipose tissue, or that a compensatory increase in activity of 
known GPATs occurs at a post-transcriptional level.  It is also possible that differences exist 
in GPAT4 expression and activity in WAT of male and female mice, as Gpat4 mRNA 
expression is lower in parametrial fat than in epididymal fat [4].   
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 Analysis of GPAT assay products from transfected Cos-7 cells showed that LPA was 
elevated 2-fold as a result of GPAT4 overexpression, consistent with a GPAT activity.  
Labeled PA was also increased 70% in samples from GPAT4-transfected cells, indicating 
that the LPA produced by GPAT4 can be used as a substrate for down-stream AGPAT 
enzymes in de novo glycerolipid synthesis.  The lack of a specific increase in PA only in 
samples from cells transfected with GPAT4 vs. vector is inconsistent with elevated AGPAT 
activity.  Subsequent formation of DAG did not occur, probably because the NaF in the assay 
mixture inhibits phosphatases and because lipin (phosphatidic acid phosphohydrolase) is 
primarily resident in the cytosol and would therefore be largely absent in the membrane 
preparation.     
 
The identification of two novel NEM-sensitive GPAT isoforms, GPAT3 [34] and 
GPAT4 (this paper), with different tissue specific expression patterns has revealed the 
complexity of de novo glycerolipid synthesis regulation.  More studies are needed to fully 
characterize the roles of GPAT3 and GPAT4 in liver and adipose tissue triacylglycerol 
synthesis, the mechanisms by which these isoforms are regulated during different physiologic 
states, and the effects of their glycerolipid synthetic products on downstream signaling 
pathways [208].  Importantly, it is unknown whether additional GPAT isoforms remain to be 
identified.  The so-called AGPATs 3, 4, 5, and 7 might also actually be GPAT isoforms.  
Further studies are needed to confirm the specific acyltransferase activities of these enzymes.    
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CHAPTER V  SYNTHESIS 
 
This dissertation describes two independent projects that examine the roles of GPAT 
isoforms in de novo triacylglycerol synthesis.  The results of these studies confirm the 
importance of GPAT isoforms in the regulation of TAG synthesis, and also implicate 
glycerolipid intermediates as important lipid signaling molecules involved in the regulation 
of insulin signaling pathways.  This chapter will discuss the key findings from these two 
projects and the future implications of these findings for the understanding and treatment of 
type 2 diabetes. 
 
5.1  Increased hepatic de novo glycerolipid synthesis causes insulin resistance 
Hepatic TAG accumulation has been associated with insulin resistance, but it is not clear 
whether insulin resistance causes fatty liver or whether fatty liver causes insulin resistance.  
Most models of insulin resistance are not appropriate for isolating the role of liver TAG 
accumulation in the development of insulin resistance because high-fat feeding and genetic 
manipulation of insulin or leptin signaling pathways affect multiple tissues.  To determine 
whether a liver-specific increase in TAG synthesis could cause hepatic and systemic insulin 
resistance, we overexpressed GPAT1 in rat liver with an adenoviral expression vector.  
Overexpression of GPAT1 increased hepatic LPA, DAG, and TAG content 2-fold above Ad-
GFP control liver lipid levels.  This increase in liver glycerolipid 
 mass was associated with hepatic and systemic insulin resistance in Ad-GPAT1-treated rats.  
Ad-GPAT-1-treatment did not increase GPAT1 expression in adipose tissue, and Ad-GPAT1 
and Ad-EGFP-treated rats did not differ in body weight or fat pad mass, indicating that the 
primary disturbance in lipid metabolism occurred in liver, not in adipose tissue.  Elevated 
plasma VLDL-TAG levels in Ad-GPAT1-treated rats may have contributed to elevated 
skeletal muscle TAG content and, subsequently, to the decrease in insulin-mediated glucose 
uptake by skeletal muscle.  PKCε translocation to the plasma membrane was elevated in liver 
from Ad-GPAT1-treated rats, implicating DAG-mediated activation of PKCε in the 
mechanism of hepatic insulin resistance caused by GPAT1 overexpression.  Immune 
mediators of insulin resistance, such as NFκB, IL-6, and TNFα, were not elevated in plasma 
or liver from Ad-GPAT1-treated rats, suggesting that the mechanism of insulin resistance 
was not immune-mediated.  
 
The most important finding from this study was that systemic insulin resistance can 
develop when hepatic de novo glycerolipid synthesis is elevated, suggesting that hepatic lipid 
accumulation and the subsequent development of hepatic insulin resistance could initiate the 
development of systemic insulin resistance.  The second most important finding of this study 
is that a glycerolipid metabolite plays an important role in the mechanism of hepatic insulin 
resistance.  Our finding that hepatic insulin resistance was associated with elevated hepatic 
DAG content and increased PKCε translocation supports earlier findings in GPAT1-/- mice 
that increased hepatic insulin sensitivity is associated with decreased hepatic DAG content 
and decreased PKCε translocation (Neschen, 2005).  These results implicate the DAG pool 
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 generated during de novo glycerolipid synthesis as a key player in the lipid-mediated 
mechanism of hepatic insulin resistance. 
 
Our study did not, however, explore the specific actions of PKCε that lead to 
inhibition of the insulin signaling pathway, nor did it prove that DAG accumulation and 
PKCε translocation are necessary for the mechanism of hepatic insulin resistance in Ad-
GPAT-treated rats.  Other studies have associated increased DAG accumulation and PKCε 
translocation, with reductions in IRS-1/2 associated PI3K activity and Akt2 activity, but 
these are only associations (Neschen, 2005; Samuel, 2003).  One way to show that PKCε 
activation is necessary for GPAT1-mediated hepatic insulin resistance would be to 
simultaneously treat rats with adenoviruses for GPAT1 and for a shRNA against PKCε.  If 
knock-down of PKCε could prevent the hepatic insulin resistance caused by GPAT1 
overexpression, then we would know that PKCε activation is involved in the inhibition of 
insulin signaling.  A similar experiment has been done in rats fed high-fat safflower oil diets 
in which knock-down of PKCε prevents diet-induced hepatic insulin resistance [129].  In this 
study, a reduction in PKCε prevents diet-induced inactivation of insulin signaling through 
IRS-2, and evidence for a direct interaction between PKCε and the incsulin receptor are 
presented.  Taken together, these studies strongly suggest that accumulation of hepatic DAG 
activates PKCε, which inhibits insulin receptor signaling by preventing the activation of IRS-
2. 
 
In addition to confirming the role of PKCε in the mechanism of hepatic insulin 
resistance in Ad-GPAT1-treated rats, it is also important to confirm that DAG derived from 
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 de novo glycerolipid synthesis is responsible for activation of PKCε and subsequent 
inactivation of insulin signaling.  DAG can also be synthesized from membrane 
phospholipids by PLC and PLD, and label incorporation into PC was 30% reduced in CHO 
cells that stably overexpressed GPAT1 [38].  Increased PLC or PLD activity could explain 
this reduction in PC labeling with GPAT1 overexpression, and the DAG produced from these 
phospholipase reactions could contribute to the DAG that accumulates in hepatocytes. Could 
overexpression of GPAT1 cause increased PLC and/or PLD activity, leading to increased 
DAG that could be used for intracellular signaling, such as activation of PKCε?  To 
determine whether DAG accumulation is involved in the mechanism of hepatic insulin 
resistance and to determine which DAG synthesis pathway is involved, I would treat rats 
simultaneously with adenoviruses expressing GPAT1 and either shRNA against one of the 
phosphatidic acid phosphohydrolases, or shRNA against PLC or PLD.  These experiments 
would determine which pools of DAG might be involved in the mechanism of insulin 
resistance in Ad-GPAT-1 treated rats.  If DAG is involved, then knock-down of one or more 
of the enzymes that synthesizes DAG should reduce that DAG pool and prevent Ad-GPAT1-
treated rats from developing hepatic insulin resistance.  
 
Recently, another research group has attempted to confirm that TAG is not the lipid 
mediator responsible for hepatic insulin resistance. These investigators treated high-fat 
safflower oil fed rats with antisense oligonucleotides (ASO) to DGAT1 or DGAT2, the 
enzymes which convert DAG to TAG [209].  The authors hypothesized that a reduction in 
hepatic TAG content due to knock-down of DGAT would fail to protect rats from diet-
induced hepatic insulin resistance because DAG content would increase in rats treated with 
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 DGAT ASOs.  As expected, DGAT1 ASO treatment did not protect rats from high-fat-diet 
induced insulin resistance. However, knock-down of DGAT1 did not affect hepatic TAG 
content, despite a significant decrease in hepatic DGAT1 activity.  DGAT1 is not the 
predominant DGAT isoform in liver, which may explain why knock-down of DGAT-1 did 
not alter the hepatic TAG content. Surprisingly, however, rats treated with DGAT2 ASO 
were protected from diet-induced insulin resistance, and hepatic DAG content was reduced, 
not increased.  This reduction in hepatic DAG was associated with reduced PKCε 
translocation and increased IRS-2 associated PI3K activity. These results support the 
hypothesis that hepatic DAG is involved in the mechanism of hepatic insulin resistance, but 
because both hepatic DAG and TAG content were reduced, they do not rule out TAG as a 
lipid mediator of insulin resistance.  Additionally, this study is complicated by simultaneous 
knock-down of DGAT2 in both liver and adipose tissue, and the authors did not adequately 
explore the role of DGAT2 knock-down in adipose tissue on the protective effects of the 
ASO treatment.  Further studies are needed to determine conclusively whether DAG is an 
important lipid mediator of hepatic insulin resistance.  
 
In addition to DAG, LPA and PA produced during de novo triacylglycerol synthesis 
could act as lipid mediators of insulin resistance.  Both PA and LPA are known to have 
important functions in intracellular signaling pathways, and LPA does accumulate in the 
livers of Ad-GPAT1-treated rats.  Although the literature does not report a mechanism for 
LPA-mediated insulin resistance, it is possible that LPA signaling could be involved. 
Simultaneous adenovirus-mediated overexpression of GPAT1 and AGPAT1 or 2 might be 
expected to reduce the LPA accumulation seen in liver from Ad-GPAT1-treated rats.  If 
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 reducing hepatic LPA protected Ad-GPAT1-treated rats from hepatic insulin resistance, then 
one would conclude that LPA must be involved in the mechanism of hepatic insulin 
resistance.  Alternately, if reducing hepatic LPA content did not protect Ad-GPAT1-treated 
rats from developing hepatic insulin resistance, then glycerolipid intermediates such as PA or 
DAG may be involved.  Adenovirus-mediated knock-down and overexpression of AGPAT 
isoforms might shed light on the role of PA as a lipid mediator of insulin resistance.  Studies 
like these are needed to tease-out the roles of individual glycerolipid metabolites in the 
mechanism of hepatic insulin resistance.  
 
5.2 Sphingolipids and Insulin Resistance in Ad-GPAT1-treated Rats and GPAT1-/- Mice 
One of the weaknesses of our proposed mechanism for insulin resistance in Ad-
GPAT1-treated rats is that we did not show a definite cause-effect relationship between the 
accumulation of DAG and activation of PKCε or between activation of PKCε and insulin 
resistance.  Although preventing the activation of PKCε in rats fed a high safflower oil diet 
(primarily linoleate) prevented the development of hepatic insulin resistance (Samuel, 2007), 
there is still no definitive proof that DAG accumulation activates PKCε.  Another lipid that 
activates PKC isoforms is ceramide, and recent bioinformatics data associate ceramide and 
DAG with hepatic steatosis and insulin resistance in ob/ob mice [210].   Thus, ceramide may 
be an important mediator of hepatic insulin resistance. 
 
Ceramide can be synthesized from palmitoyl-CoA and serine by serine palmitoyl 
transferase (SPT) and ceramide synthase, and from sphingomyelin by sphingomyelinase 
(SMAse) at several intracellular locations (Figure 2.5). The regulation of de novo ceramide 
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 synthesis appears to depend largely on the availability of palmitoyl-CoA, and inhibiting 
CPT-1 increases ceramide production in the presence of palmitoyl-CoA [138, 211].  
Increased TAG synthesis and storage has also been associated with increased ceramide 
production [136].  Because GPAT1 has a substrate preference for palmitoyl-CoA and 
because overexpression of GPAT1 in primary hepatocytes results in a reduction in beta-
oxidation, it is possible that over-expression of GPAT1 could increase de novo ceramide 
production in hepatocytes.  Decreased oxidation of palmitoyl-CoA due to increased 
production of malonyl-CoA during de novo lipogenesis might result in increased synthesis of 
TAG and ceramide, leading to insulin resistance (Figure 2.6).  On the other hand, 
overexpression of GPAT1 could reduce the palmitoyl-CoA available for de novo ceramide 
synthesis and prevent the accumulation of ceramide (Figure 2.7).  If ceramide accumulation 
is altered in liver from Ad-GPAT1-treated rats, then DAG accumulation may not be the only 
lipid causing insulin resistance in this model. 
 
Recently, an important publication in Cell Metabolism demonstrated that intravenous 
infusion of a soybean-oil-based diet (primarily linoleate) causes insulin resistance that is 
associated with increased hepatic DAG accumulation, whereas intravenous infusion of a lard-
oil diet (primarily palmitate and stearate) causes insulin resistance that is associated with 
hepatic increases in ceramide and DAG [104].  Furthermore, hepatic insulin resistance was 
prevented by myriocin, an inhibitor of serine palmitoyl transferase (SPT), in the lard-oil 
group but not in the soybean oil group [104].  This protective effect of myriocin was 
attributed to a reduction in hepatic ceramide content only in the lard oil group.  DAG content 
was not affected by myriocin in either diet group.   
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As I explained in section 2.9, the affects of GPAT1 deficiency on ceramide and DAG 
accumulation may explain why GPAT1-/- mice fed a high-fat safflower oil diet were 
protected from insulin resistance, whereas GPAT1-/- mice fed a high-saturated/high-sucrose 
diet were more insulin resistant than their wild-type controls.  The following statements are a 
review of that hypothesis.  If one assumes that in mice fed the high-fat safflower oil diet, the 
mechanism of insulin resistance is primarily mediated by DAG, then reducing DAG would 
protect these mice from developing insulin resistance.  Thus, GPAT1-/- mice fed the high-fat 
safflower oil diet were protected from insulin resistance because they had less hepatic DAG 
accumulation and less PKCε activation. [14].  However, GPAT1-/- mice fed the high fat/high 
sucrose diet (HH) were not protected from hepatic insulin resistance because this diet 
provided palmitate (40 g/ 5777 kg) from the high fat content and from de novo lipogenesis 
(increased by the high sucrose diet).  In fact, GPAT-/- mice were more insulin resistant than 
their wild-type controls, perhaps because palmitate was more readily available for ceramide 
synthesis.  Increased ceramide synthesis might occur for several reasons.  First, the use of 
palmitoyl-CoA for glyceorlipid synthesis was reduced due to knock-out of GPAT1.  
Secondly, the enzymes that perform β-oxidation were inundated by fatty acids from the high-
fat diet, and CPT1 was inhibited by elevated de novo lipogenesis, thus blocking the oxidation 
of palmitate.  To determine whether these ideas are correct, we would have to measure 
hepatic ceramide content in GPAT1-/- mice fed either the high-fat safflower oil diet or the HH 
diet.  If ceramide is elevated in livers from GPAT1-/- mice on the HH diet, we could inhibit 
ceramide synthesis with myriocin or an ASO against SPT to determine whether reducing 
ceramide would restore insulin sensitivity.  
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With the exception of our Ad-GPAT1 study, all of the studies that have suggested a 
DAG-PKCε or a DAG-PKCδ mechanism for the development of hepatic insulin resistance 
have used a linoleate-based diet to cause insulin resistance, [14, 119, 120, 129, 209].  Thus, 
the proposed role of PKCε and PKCδ in the development of high-fat-diet-induced hepatic 
insulin resistance may only be relevant to diets high in linoleate or other polyunsaturated 
fatty acids.  Because humans eat diets high in both saturated and polyunsaturated fatty acids, 
models of diet-induced insulin resistance that are high in one type of fatty acid may not be 
relevant to human insulin resistance.  Further studies are needed to determine whether PKCε 
is required for the development of insulin resistance in other models of insulin resistance.  
ASO-mediated knock-down of PKCε in ob/ob mice and in mice fed diets in lard or high in 
sucrose might answer this question. 
 
5.3 De novo glycerolipid synthesis and modulation of the hepatic acute immune 
response 
Although many recent studies of hepatic and systemic insulin resistance have 
implicated the activation of the acute immune response as an important step in the 
mechanism of insulin resistance, we did not find any evidence for an elevated immune 
response in Ad-GPAT1-treated rats.  In fact, we found that GPAT1 overexpression 
consistently suppresses NFκB activity.  NFκB activity was suppressed in primary 
hepatocytes treated with Ad-GPAT1, and the stable expression of GPAT1 in CHO cells 
suppressed the activity of the NFκB luciferase reporter (unpublished data, C.A.N and Cliona 
Stapelton).  These experiments suggest that changes in GPAT1 activity can modulate the 
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 binding of NFκB to its DNA binding sequence.  One explanation for this observation is that 
overexpression of GPAT1 reduces reactive oxygen species (ROS) produced as a byproduct 
of β-oxidation.  NFκB is re-dox sensitive, and can be activated by oxidative stress.  Because 
livers from GPAT1-/- mice have increased markers of oxidative stress, it is plausible that 
reduced β-oxidation and ROS production in the livers of Ad-GPAT1-treated rats reduces 
normal levels of active NFκB [178].  Another possible explanation for the GPAT1-mediated 
reduction in NFκB activity is that LPA produced by GPAT activates PPARγ, which can 
inhibit NFκB activity.  It is well known that activation of PPARγ can inhibit NFκB activity 
[17], and LPA may be an endogenous ligand for PPARγ [74].  Additionally, stable 
overexpression of GPAT1 in CHO cells activated PPARγ DNA binding to a PPRE luciferase 
reporter construct (unpublished data, Cliona Stapleton). Additional experiments designed to 
examine the role of GPAT1-derived LPA-mediated activation of PPARγ would clarify the 
mechanism of reduced NFκB activity observed when GPAT1 activity is elevated.  These 
studies might include overexpression of GPAT1 in PPARγ deficient hepatocytes.  If GPAT1 
overexpression fails to suppress NFκB activity in primary hepatocyes that lack PPARγ, then 
the suppression must occur via a PPARγ-mediated mechanism.   
 
5.4 The Future of Insulin Resistance Research – Putting it All Together 
In the past several years there have been numerous reports of “essential” 
inflammatory and lipid mediators of insulin resistance.  Knock-down studies have implicated 
NFκB, TNFα, IL-6, DAG, and ceramide as "essential" mediators of insulin resistance in 
high-fat fed or genetically insulin resistant animals, but how can all of these mediators be 
essential?  Is there one silver bullet in a long sequence of events that lead to systemic insulin 
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 resistance?  Where does this sequence to insulin resistance begin, and what is the final step?  
Is the sequence really linear, or is it somewhat circular?  Future studies that can answer 
questions about this sequence of events are needed so that the most effective pharmalogical 
treatments and preventative strategies can be developed. 
 
5.5  GPAT3 (AGPAT6) is the hepatic erGPAT isoform 
 AGPAT6 is a novel acyltransferase that was classified as an AGPAT based on amino 
acid sequence similarity to AGPAT1 and AGPAT2.  However, AGPAT6 also shares 
sequence homology with GPAT isoforms at the same conserved acyltransferase motifs, and 
no specific acyltransferase activity for AGPAT6 was measured [4].  AGPAT6 -/- mice are 
deficient in TAG in liver and adipose tissue, a phenotype that could be explained by a 
deficiency in either GPAT or AGPAT activity. The recent discovery that GPAT3 had been 
misclassified as AGPAT8, and the 66% amino acid sequence similarity of GPAT3 and 
AGPAT6 prompted us to measure both AGPAT and GPAT activities in AGPAT6-/- mouse 
tissues.  We found that NEM sensitive GPAT activity was decreased 65% in liver and brown 
adipose tissue from AGPAT6-/- mice.  AGPAT activity did not differ in those tissues.  To 
confirm that AGPAT6 catalyzes GPAT activity, we overexpressed AGPAT6 in Cos-7 cells.  
Cos-7 cells transfected with AGPAT6 had increased NEM-sensitive GPAT activity, and 
AGPAT activity did not differ in total membrane preparations from AGPAT6 and vector 
control transfected cells.  Thus, we have identified a novel NEM-sensitive GPAT, GPAT4, 
located in the endoplasmic reticulum of liver and brown adipose tissue.  Importantly, 
identifying the primary erGPAT isoform in liver allows further study of the regulation of 
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 hepatic de novo glycerolipid synthesis that was not possible before GPAT4 was cloned and 
identified. 
 
5.6  Functional role of GPAT4 in hepatocytes: 
 Now that there are 4 known GPAT isoforms, there is a lot of work to be done in 
characterizing their individual roles in regulating glycerolipid metabolism in different tissues 
and under different physiologic conditions.  In particular, GPAT4 is the primary erGPAT 
isoform in liver, and its activity accounts for ~33 % of total liver GPAT activity.  How does 
the role of GPAT4 differ from that of GPAT1? One way to begin to answer this question is to 
examine the incorporation of labeled fatty acids into glycerolipids in hepatocytes that either 
overexpress or are deficient in GPAT4. These experiments would tell us what proportion of 
labeled fatty acid is incorporated into PL, CE, and TAG.  It would also be interesting to 
determine whether altering GPAT4 activity would cause reciprocal regulation of fatty acid 
oxidation similar to that seen with changes in GPAT1 activity.  Because GPAT4 is located on 
the ER and not on mitochondria, I would suspect that overexpression of GPAT4 would not 
decrease β-oxidation in the same way as overexpression of GPAT1 does.  Because the role of 
GPAT4 in TAG synthesis might be different under different nutritional conditions, it would 
be interesting to determine what happens to fatty acid label incorporation under conditions of 
high and low media fatty acid content, high and low glucose content, and combinations of 
high/low glucose and high and low/fatty acids.  
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 5.7  Transcriptional regulation of GPAT4 by hormones: 
One of the important questions that can be addressed now that GPAT4 has been 
identified is how it is transcriptionally regulated in liver and other tissues.  GPAT1 
expression and activity are regulated by insulin, suggesting both transcriptional and post-
translational regulatory mechanisms.  Insulin, however, does not appear to regulate GPAT4 
in the same manner as GPAT1, since hepatic NEM-sensitive activity does not change in rats 
that are fasted and re-fed [29].  However, regulation of GPAT4 activity by insulin could be 
hidden by reciprocal changes in the activity of other NEM-sensitive GPAT isoforms present 
in liver, such as GPAT3.  
 
If GPAT4 is not regulated by nutritional status, then how is it regulated?  The fact 
that GPAT4-/- mice were unable to produce enough lipid for proper lactation suggests that 
GPAT4 is necessary for milk production.  During pregnancy, estrogen and progesterone 
stimulate the breasts to lay down fat in preparation for milk production, and prolactin and 
growth hormone stimulate the proliferation and differentiation of mammary epithelial cells 
through activation of STAT 5 [212].  Thus, GPAT4 may be transcriptionally regulated by 
estrogen, progesterone, prolactin, or growth hormone.  To determine whether one of these 
hormones regulates GPAT4 expression in hepatocytes, I would measure GPAT4 mRNA 
expression and activity in untreated and hormone treated primary rat hepatocytes.  
 
Another possible transcriptional activator of GPAT4 might be PPARγ, which is 
known to activate a large number of lipogenic genes, especially those related to adipocyte 
differentiation.  Since GPAT4 is expressed in adipose tissue, and its expression increases 
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 during early pre-adipocyte differentiation (unpublished data L. Vergnes), it is possible that it 
is regulated by PPARγ.  Even though PPARγ does not play a primary role in regulating 
hepatic lipogenic gene expression under normal physiologic conditions, PPARγ is up 
regulated in many animal models of fatty liver (Schadinger, 2005), and PPARγ agonists, 
which are commonly used to treat diabetes, can cause an increase in hepatic lipid 
accumulation [213].  It would be interesting to know whether GPAT4 is partially responsible 
for the increase in hepatic lipids caused by PPARγ agonists. To test this hypothesis, I would 
treat primary hepatocytes with a PPARγ agonist, such as rosiglitizone, and measure GPAT4 
mRNA expression in untreated and treated cells.  A better understanding of the regulation of 
GPAT4 in hepatocytes would improve our knowledge of hepatic glycerolipid synthesis 
during different physiologic conditions. 
 
5.7  Does GPAT4 modulate insulin sensitivity? 
Hepatic overexpression of GPAT1 causes insulin resistance, possibly through 
elevation in hepatic LPA or DAG content.  Although selective knockout of either GPAT1 or 
GPAT4 reduces hepatic TAG content, suggesting that they both regulate TAG synthesis, it is 
not clear whether the two isoforms channel glycerolipid products into separate functional 
pools.  This idea is particularly important for LPA, PA, or DAG, which may have functions 
in intracellular signaling pathways.  If GPAT1 and GPAT4 synthesize different pools of 
DAG, then it is possible that one pool would affect PKC activation and insulin signaling and 
the other pool would not.  To address those questions, future studies could investigate the 
effects of knockdown or overexpression of GPAT4 in liver on hepatic and systemic insulin 
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sensitivity in relation to the amount of LPC, PA, and DAG that accumulate in the liver tissue 
under those conditions.   
  
5.8  Public Health Significance 
The prevalence of obesity and its co morbidities, including nonalcoholic fatty liver 
disease, cardiovascular disease and type 2 diabetes, are increasing at a rapid rate in the US 
and world-wide, affecting both adult and child populations.  These chronic diseases are 
characterized by disturbances in the normal regulation of lipid and carbohydrate metabolism.  
Thus, a solid understanding of the regulation of lipid metabolism is vital to our ability to treat 
and prevent chronic disease.  GPAT and AGPAT isoforms are important enzymes that 
regulate glycerolipid metabolism and intracellular signaling by glycerolipid metabolites.  
Work reported in this dissertation has improved our knowledge of the role of GPAT1 in 
regulating diacylglyerol synthesis for intracellular signaling pathways that can inhibit insulin 
signaling and cause hepatic insulin resistance.  Additionally, increased hepatic GPAT1 
activity caused hyperlipidemia, which is a risk factor for cardiovascular disease. Further 
studies might explore the possibility of developing a GPAT1 inhibitor to treat type 2 diabetes 
and hyperlipidemia.  GPAT3, which was recently identified as an important regulator of 
TAG synthesis in white adipose tissue, may also affect insulin sensitivity in adipose tissue 
and the development of obesity.  Further studies might explore the possibility of developing 
GPAT3 specific inhibitors as treatments for obesity and diabetes. 
 
In addition to their role in energy regulation, GPAT isoforms are important for the 
regulation of glycerolipid synthesis in reproductive tissues, such as mammary tissue and 
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testis.  GPAT4-/- mice are unable to make enough lipid-rich milk to feed their pups, 
indicating a vital role for GPAT4 in milk production.  Additionally, GPAT4-/- mice had fewer 
and smaller alveoli than wild-type mice, suggesting that glycerolipid signaling could be 
involved in the proliferation of mammary epithelia. Further studies might explore the role of 
aberrant GPAT4 activity in the proliferation and differentiation of mammary epithelium and 
the development of mammary epithelial tumors. 
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